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SMALL MOLECULE DRUG RELEASE FROM
IN SITU FORMING DEGRADABLE
SCAFFOLDS INCORPORATING
HYDROGELS AND BIOCERAMIC
MICRO PARTICLES

provides an injectable system for recovering bone or periodontal tissue that provides for sustained drug delivery with
structural support.

RELATED APPLICATIONS

The present invention provides an injectable system for
assisting in osseous tissue repair, the system comprising a
degradable matrix in a solvent, a hydrogel and a ceramic.
The degradable matrix may be selected from PLGA, poly
(lactic acid) and poly(E-caprolactone). The ceramic may be
selected from the group consisting ofhydroxyapatite (HA),
brushite, calcium polyphosphate, ~-tricalcium phosphate,
and monetite. PLGA may comprise different L:G ratios,
such as between 50:50 to 95:5, further up to 100:0 to include
poly( acetic acid) or 0: 100 for poly(glycolic acid. PLGA may
comprise a molecular weight range between 5 and 300 kDa
and an endcap of carboxylate or an ester-linked hydrocarbon. The hydrogel may be selected from the group consisting of poly(~-amino ester) (PBAE), methoxy poly(ethylene
glycol)-poly(lactic-co-glycolide), poly( ethylene glycol)poly(lactic-co-glycolide)-poly(ethylene glycol), alginate
hydrogels, and hyaluronan hydrogels-poly(lactic-co-valerolactone ). The solvent may be selected from the group
consisting of N-methyl-2-pyrrolidone, dimethyl sulfoxide,
ethyl acetate, ethyl benzoate, and triacetin.
In certain embodiments, the injectable system may comprise between 15 and 45 w/w % as the degradable matrix and
between 15 and 45 w/w % (+/-10%) as the ceramic and
between 3-25 w/w % (+/-10%) as the hydrogel. In other
embodiments, the injectable system may comprise 193 w/w
% degradable matrix, 45.5 w/w % solvent, 30 w/w %
ceramic and 5 w/w % drug-loaded hydrogel. In yet further
embodiments, the injectable system may comprise 18 w/w
% degradable matrix, 42 w/w % solvent, 30 w/w % ceramic
and 10 w/w % drug-loaded hydrogel.
The hydrogel may be pre-loaded with a therapeutic agent.
For example, the therapeutic agent may be selected from the
group consisting of coldronate, alendronate, etidronate,
zoledronate, simvastatin, lovastatin, rosuvastatin, SVAK-12,
bone morphogenetic proteins, parathyroid hormone (1-34),
metronidazole, doxycycline, vancomycin, gentamycin, ciprofloxacin, ketoprofen, celecoxib, diclofenac, meloxicam or
mixtures thereof.
The present invention also provides methods of preparing
an in situ injectable system for osseous tissue, comprising
mixing a hydrogel, a ceramic and a degradable matrix. The
hydrogel may be preloaded or be admixed at the point of
care with at least one pharmaceutical agent. The degradable
matrix may be further cross-linked. The hydrogel may be
mixed with the degradable matrix prior to cross-linking.

This application claims priority to U.S. Provisional Patent
Application 61/975,139, filed 4 Apr. 2014, which is hereby
incorporated by reference in its entirety.

SUMMARY OF THE INVENTION
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GOVERNMENT INTEREST
This invention was made with Government support from
National Institutes of Health grant AR060964 and National
Science Foundation grants EPS-0814194 and DGE0653710. The Government may have certain rights in the
invention.
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TECHNICAL FIELD
The present invention relates generally to injectable scaffolds for sustained drug delivery in recovering tissues, such
as bone and the periodontium.
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BACKGROUND
In situ forming implants ("ISis") have been investigated
primarily for injection into soft tissue for sustained drug
delivery (Hatefi A, Amsden B. Biodegradable injectable in
situ forming drug delivery systems. Journal of Controlled
Release 2002; 80(1-3):9-28). These systems were conceived
due to the phase separation observed when a hydrophobic
polymer dissolved in a water-miscible organic solvent is
introduced to an aqueous environment, resulting in solidification of the polymer matrix (Shah NH, Railkar AS, Chen
F C, Tarantino R, Kumar S, Murjani M, Palmer D, Infeld M
H, Malick A W. A biodegradable injectable implant for
delivering micro and macromolecules using poly(lactic-coglycolic) acid (PLGA) copolymers. Journal of Controlled
Release 1993; 27(2):139-147), By mixing drugs into the
polymer phase prior to injection, a drug-loaded, solid depot
can form upon injection into the body. Such systems are
available in FDA-approved formulations, such as ATRIDOX®, for delivery of doxycycline into gum tissue, and
ATRIGEL®, which is approved for delivery of leuprolide
acetate for treatment of prostate cancer. These systems
provide prolonged drug release, with an initial burst dependent on drug and solvent properties and a release period
dependent on drug and polymer properties (Parent M, Nouvel C, Koerber M, Sapin A, Maincent P, Boudier A. PLGA
in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release. Journal of
Controlled Release 2013; 172(1):292-304). As such, these
injectable systems avoid the additional trauma that would be
needed for implantation of large, solid dosage forms. Furthermore, the polymers are hydrolytically degradable, so
there is no secondary surgery required to remove an implant
after drug delivery is complete (Kenley R A, Lee M 0,
Mahoney T R, Sanders L M, Poly(lactide-co-glycolide)
decomposition kinetics in vivo and in vitro. Macromolecules
1987; 20(10):2398-2403). Because these polymer systems
are locally injectable and space-filling, they should be able
to infiltrate and conform to complex geometries, such as a
network of trabecular bone. However, these materials offer
little in the way of structural support. The present invention
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FIG. 1 shows mechanical properties of cylindrical scaffolds prepared with different MHA content and tested at
multiple strain rates. A) Compressive modulus. B) Yield
stress. Data are grouped by displacement rate and ordered by
increasing MHA content. Shared letters denote statistical
similarity, and columns without a single shared letter are
significantly different. Data are mean±standard deviation
(n=3).
FIG. 2 shows representations of viscosity and mechanical
properties for scaffolds containing various hydrogel
microparticle content, formulated with 30% total NHA and
the remainder of the weight composed of 30% PLGA in
NMP. Shared letters denote statistical similarity, and col-
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umns without a single shared letter are significantly different. Data are mean±standard deviation (n=3).
FIG. 3 shows, using SAWBONES® open cell rigid polyurethane foams made to mimic trabecular bone architecture,
two 5x5x5 mm3 samples with and without the mixture
injected, demonstrating the space-filling capability of the
mixture. The samples receiving injections were immersed in
buffer for 3 days to ensure complete solidification of the
PLGA. Also included are graphs showing mechanical properties of Sawbones injected with varying weight percentages
of NHA and MHA. Again, 30% NHA provided the most
benefit, and 15% NHA/15% MHAwere comparable. Modulus is lower than pure scaffolds due to imperfect geometry
and the inferior mechanical properties of the Sawbones
themselves.
FIG. 4 shows PBAE particles, with unbound HA
microparticles (black arrows) and PBAE hydrogel (white
arrows) labeled. HA particles can also been seen coating the
PBAE particles. At the highest magnification, HA microparticles can be seen to be composed of aggregated nanoparticles.
FIG. 5 shows composite PBAE particles, with homogeneous distribution of HA throughout particles. HA and
PBAE are indistinguishable, though at higher magnification,
spherical nanostructures can be seen all over the surface of
the material. Because PBAE was polymerized around HA,
there is no discrete HA powder visible, and all HA content
is encased in polymer, which supports the superior drug
loading properties of these composite microparticles.
FIG. 6 shows PBAE microparticle and injectable scaffold
fabrication process. A) Technique for formation of PBAE
hydrogels and processing them into drug-containing pre- or
post-loaded microparticles. B) Comparison of a traditional
injectable PLGA system (right) to the proposed system
(left).
FIG. 7 shows drug loading into PBAE hydrogel. A)
Simvastatin loading after soaking in 100% ethanol solutions
for 24 hours. B) Loading after soaking in 50% ethanol
clodronate solution for 24 hours. C) Loading after immersion in aqueous clodronate solution for 24 hours. Data are
mean±standard deviation (n=3).
FIG. 8 shows morphology, composition, and swelling of
PBAE microparticles. A) SEM image of a PBAE microparticle, with EDS performed on the highlighted portion. B)
Top left: Region chosen from (A) for EDS analysis, with
arrows indicating points of spectral analysis performed in
(C). Bottom left: Composite overlay of calcium and phosphorous on that region. Top right: EDS detection of calcium.
Bottom right: EDS detection of phosphorous. B). C) EDS
spectra of an HA particle (upper right) and PBAE (lower
right). D) PBAE swelling kinetics expressed as a percentage
of mass increase in injection mixture (30 wt % HA mixed
into 20% PLGA solution). Data are mean±standard deviation (n=3).
FIG. 9 shows surface vs. bulk loading in microparticles:
A) simvastatin post-loaded, C) simvastatin pre-loaded, and
E) clodronate pre-loaded. Loading efficiency: B) postloaded simvastatin, D) pre-loaded simvastatin, and F) preloaded clodronate. Data are mean±standard deviation (n=3).
FIG. 10 shows cumulative release profiles. A) Release of
simvastatin loaded freely into the PLGA solution with (fl) or
without HA ( o ), or loaded into PBAE (□) (n=3). B) Release
of clodronate freely loaded into PLGA solution with (fl) or
without HA ( o ), or loaded into PBAE microparticles ( □)
(n=4). Data are mean±standard deviation.
FIG. 11 shows degradation of in situ forming PLGA
scaffolds. A) Destructive mass loss showing dry mass

change expressed as a fraction of pre-injection mass (n=3).
B) Non-destructive mass loss showing total hydrated scaffold mass change, expressed as a fraction of pre-injection
volume (n=5). Data are mean±standard deviation.
FIG. 12 shows representative microCT cut-plane images
of lyophilized scaffolds showing internal microarchitecture
throughout the degradation process. Scale bars are 1 mm.
FIG. 13 shows morphometric parameters during degradation. A) Porosity and B) average pore size measured by
microCT evaluation of samples through 35 days.
FIG. 14 shows mechanical properties of scaffolds prepared with different MHA:NHA ratios, grouped by increasing total HA content (w/w %) and subsequently ordered by
increasing MHA content (w/w %). A) Compressive modu!us. B) Yield stress. Shared letters denote statistical similarity, and columns without a single shared letter are significantly different. Data are mean±standard deviation (n=3).
FIG. 15 shows injectability of 30% NHA scaffold mixtures prepared with varying PBAE microparticle content. A)
Representative graph of collected force (green curve, left
axis) and displacement (blue curve, right axis) data, with the
highlighted linear portion of the displacement used to calculate volumetric flow rate. B) Time required to inject 0.5
mL from a 16 gauge needle for various injection forces and
PBAE microparticle contents. The dotted lines indicate
reasonable limits for injection time for 0.5 mL (60 sec) and
injection force (50 N). Data are mean±standard deviation
(n=3).
FIG. 16 shows SEM images of 30% w/w NHA scaffold
microarchitecture, showing A) macropores on the order of
100 µm (white arrows), B) microporous PLGA substructure,
C) elongated pores perpendicular to the surface (dotted
arrows), and D) NHAnanoparticles embedded in the PLGA
matrix (black arrows).
FIG. 17 shows microCT analysis of scaffolds prepared
with varying NHA and MHA content, showing A) porosity
and B) material density of cylindrical samples. Data are
grouped by total HA content, and ordered by increasing
NHA content. Shared letters denote statistical similarity, and
columns without a single shared letter are significantly
different. Data are mean±-standard deviation (n=3).
FIG. 18 shows microstructural and mechanical properties
of trabecular bone samples from porcine humeral heads with
or without injection of 30% NHA/5% PBAE scaffolds. A)
MicroCT cutplane of humeral head prior to injection (left)
and post-injection (right). B) Cylindrical bone sample containing solidified scaffold. C) Compressive modulus. D)
Yield stress. Data are mean±-standard deviation (n=7).
*Significantly different from Control (p<0.001). **Significantly different from Control (p<0.01). Scale bar is 5 mm.
FIG. 19 shows mass loss of ISis. Remaining dry mass of
A) HMW scaffolds and C) LMW scaffolds. Remaining wet
mass ofB) HMW scaffolds and D) LMW scaffolds. Data are
mean±standard deviation (n=3).
FIG. 20 shows bisected microCT reconstructions of
HMW ISis containing no additives (Control) or 10% PBAE
particles (H, AH, or H/AH). White indicates material present
in the cut plane. Arrows indicate solid material within pores.
FIG. 21 shows microarchitecture of HMW scaffolds
throughout degradation. A) Porosity and B) mass-normalized volume of scaffolds, evaluated using microCT. Accessibility of C) scaffold volume and D) mass-normalized
surface area to a simulated 24 µm sphere. Data are
mean±standard deviation (n=3).
FIG. 22 shows interfacial strength measured from pushout tests on cylindrical samples within gelatin molds. Data
are mean±standard deviation (n=3).
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FIG. 23 shows mechanical properties of cylindrical
implants subjected to 30 cycles of 1% compressive strain at
1 Hz. A) Initial and 30-cycle modulus. B) Ratio of initial to
30-cycle modulus. C) Initial and 30-cycle resilience. D)
Ratio of initial to 30-cycle resilience. Data are
mean±standard deviation (n=3).
FIG. 24 shows simvastatin release from A) HMW and B)
LMW scaffolds. D+S indicates that scaffolds were co-loaded
with simvastatin and doxycycline. Data are mean±standard
deviation (n=3).
FIG. 25 shows doxycycline release from A) HMW and B)
LMW ISis. D+S indicates that scaffolds were co-loaded with
simvastatin and doxycycline. Pre indicates that doxycycline
was pre-loaded into PBAE microparticles. Data are
mean±standard deviation (n=3).

reinforced in situ forming PLGA systems for intraosseous
injection, J. Biomed. Mater. Res. Part A, doi: 10.1002/
jbm.a.35375; Fisher, P. D., Clemens, J., Hilt, J. Z., and
Puleo, D. A. (2015). Multifunctional poly(~-amino ester)
hydrogel microparticles in periodontal in situ forming drug
delivery systems (in review); Fisher, P. D., Milbrandt, T. M.,
Hilt, J. Z., and Puleo, D. A. (2013). In situ forming drug
delivery scaffold for treating avascular necrosis of the femoral head. Presented at the 2013 Annual Meeting of the
Society For Biomaterials, April 10-13, Boston, Mass.;
Fisher, P. D., Milbrandt, T. M., Hilt, J. Z., and Puleo, D. A.
(2014). Drug release and mechanical effects of poly(~amino ester) and hydroxyapatite on in situ forming PLGA
systems. Presented at the 2014 Annual Meeting of the
Society For Biomaterials, April 16-19, Denver, Colo.;
Fisher, P. D., Milbrandt, T. M., Hilt, J. Z., and Puleo, D. A.
(2014). Improving properties of in situ forming PLGA
implants via poly(~-amino ester) and hydroxyapatite additives. Presented at the 2014 Annual Meeting of the Biomedical Engineering Society, October 22-25, San Antonio,
Tex.; Fisher, P. D., Milbrandt, T. M., Hilt, J. Z., and Puleo,
D. A. (2015). An in situ forming, injectable PLGA composite for orthopedic applications. To be presented at the 2015
Annual Meeting of the Society For Biomaterials, April
15-18, Charlotte, N.C.
The present invention provides a system for delivery of
therapeutic and structural support into bone, joint and periodontal sites. The system of the present invention provides
a composition comprised of a degradable matrix, a ceramic,
and a hydrogel in a solvent. Suitable degradable matrices
may include, but are not limited to: PLGA with different L:G
ratio, molecular weight, and endcap; poly(lactic acid); and
poly( E-caprolactone ); suitable ceramics may include, but are
not limited to: hydroxyapatite (HA), brushite, calcium polyphosphate, ~-tricalcium phosphate, and monetite; suitable
hydrogels may include, but are not limited to: poly(~-amino
ester) (PBAE), methoxy poly(ethylene glycol)-poly(lacticco-glycolide ), poly(ethylene glycol)-poly(lactic-co-glycolide)-poly(ethylene glycol), alginate hydro gels, and
hyaluronan hydrogels; and suitable solvents may include,
but are not limited to: N-methyl-2-pyrrolidone (NMP),
dimethyl sulfoxide, ethyl acetate, ethyl benzoate, and triacetin. Hydrogels may be preloaded with a pharmaceutical
agent or admixed by a practitioner just prior to injection of
the system.
The system of the present invention may be injected into
different sites and may further incorporate multiple therapeutic agents. Accordingly, the system can be utilized in
procedures requiring improved structural support with the
added benefit of in situ sustained drug delivery. For example,
the present invention may be utilized in dental, craniofacial,
and orthopedic applications. These include adult avascular
necrosis of bone, large bone segmental defects resulting
from trauma, hip and knee replacement revision with bone
loss, reconstruction following bone tumor resection, and
treatment of periodontal defects.
The system of the present invention may further include
a therapeutic agent or more thereof within the hydrogel or
the matrix itself. Suitable therapeutic agents may comprise
agents for decreasing inflanimation, increasing osteogenesis,
preventing resorption and preventing infection. These
include, but are not limited to the following.
Antiresorptive: clodronate, alendronate, etidronate, and
zoledronate
Osteogenic: simvastatin, lovastatin, rosuvastatin, SVAK12, bone morphogenetic proteins, and parathyroid hormone (1-34)
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DESCRIPTION
Controlled drug delivery systems offer a variety of potential advantages over traditional routes of administration,
such as oral dosages and intravenous or subcutaneous injection of drug solutions, due to their spatial and temporal
control over drug release (Allen T M, Cullis P R. Drug
Delivery Systems: Entering the Mainstream. Science 2004;
303:1818-22). Traditional dosage forms result in systemic
circulation of drug, and the oral route is also subject to
first-pass metabolism (Veber D F, Johnson SR, Cheng H-V,
Smith B R, Ward K W, Kopple K D. Molecular Properties
That influence the Oral Bioavailability of Drug Candidates.
Journal of Medicinal Chemistry 2002; 45:2615-23). Injections introduce a bolus of drug at high concentrations, and
long-term treatment requires repeated dosing, resulting in
pulsatile concentration profiles (Uhrich K E, Cannizzaro S
M, Langer R S, Shakesheff K M. Polymeric systems for
controlled drug release. Chemical reviews 1999; 99:318198). Implantable drug-loaded scaffolds can be placed at the
treatment site to minimize systemic exposure and can be
designed to control release kinetics by varying the chemical
and physical nature of the carrier (Uhrich K E, Cannizzaro
S M, Langer R S, Shakesheff K M. Polymeric systems for
controlled drug release. Chemical reviews 1999; 99:318198; Garg T, Singh 0, Arora S, Murthy R. Scaffold: a novel
carrier for cell and drug delivery. Critical reviews in therapeutic drug carrier systems 2012; 29:1-63). These systems,
however, generally require a surgical procedure to implant
the device, and in the case of a non-degrading material,
require a removal surgery. As a result, significant effort in
the drug delivery field has focused on injectable, biodegradable drug carriers, such as in situ gelling, polymerizing, or
precipitating systems (Hatefi A, Amsden B. Biodegradable
injectable in situ forming drug delivery systems. Journal of
Controlled Release 2002; 80:9-28; Packhaeuser C B,
Schnieders J, Oster CG, Kissel T. In situ forming parenteral
drug delivery systems: an overview. European Journal of
Pharmaceutics and Biopharmaceutics 2004; 58:445-55). A
space-filling scaffold capable of forming into a biodegradable solid at the treatment site is an appealing option because
it can penetrate a tissue network to deliver drugs at a fixed
location with minimal invasiveness and no removal surgery.
Additional background for the present invention can be
found as follows: Fisher, P. D., Palomino, P., Milbrandt, T.
M., Hilt, J. Z., and Puleo, D. A. (2014). Improved small
molecule drug release from in situ forming polylactic-coglycolic acid) scaffolds incorporating poly(~-amino ester)
and hydroxyapatite microparticles, J. Biomater. Sci. Polym.
Ed. 25:1174-1196; Fisher, P. D., Venugopal, G., Milbrandt,
T. A., Hilt, J. Z., and Puleo, D. A. (2015). Hydroxyapatite-
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Antimicrobial: metronidazole, doxycycline, vancomycin,
gentamycin, and ciprofloxacin
Anti-inflammatory: ketoprofen, celecoxib, diclofenac,
and meloxicam
The system of the present invention offers improved
release kinetics, multiple release profiles, and rapid solidification compared to traditional in situ forming implants
(IS Is). Incorporating drug-loaded microparticles into an
injectable degradable matrix system may provide a secondary means of controlling release kinetics. Intraosseous injection in particular is a suitable application for the in situ
forming system of the present invention due to the interconnected porous network of the trabecular bone that makes
placement of pre-formed scaffolds difficult and removal
surgery impossible. The injectable degradable systems can
accommodate filler particles such as bioceramics, such as
hydroxyapatite (HA), to influence microarchitecture,
mechanical properties, or osteoconductivity.
Those skilled in the art will appreciate that the physical
characteristics of the system can be varied by altering the
concentrations of each component within the system. While,
the composition of the system can be varied significantly,
attention should include focus on resulting effects on drug
content, mechanical properties, and "injectability". One
embodiment of the present invention provides for 30 w/w %
(+/-15%) of the degradable matrix in solvent (solvent
provides 30-60 w/w %); 30 w/w % ( +/-10%) of the bioceramic particles and 5-10 w/w % (+/-10%) of the hydrogel
particles. For example, the system may comprise a 30 w/w
% PLGA solution in NMP, 30 w/w % HA nanopowder and
3-20% w/w % PBAE microparticles (depending on desired
drug loading; 10% PBAE does not affect mechanical properties but does increase viscosity, which makes the solution
more difficult to inject).
For example, in one embodiment, the system may comprise, by weight:
19.5% degradable matrix (e.g. PLGA)
45.5% solvent (e.g. NMP)
30% bioceramic (e.g. HA nanopowder)
5% drug-loaded hydrogel (e.g. PBAE microparticles)
Such compositions provide the advantage of a low viscosity
and higher injectability, but offer reduced capacity for drug
loading.
In another embodiment, the system may comprise, by
weight:
18% degradable matrix (e.g. PLGA)
42% solvent (e.g. NMP)
30% bioceramic (e.g. HA nanopowder)
10% drug-loaded hydrogel (e.g. PBAE microparticles)
Such compositions provide the advantage of increased drug
loading but with a high viscosity/lower injectability. Increasing the hydrogel microparticle content to 15% or higher has
demonstrated a negative effect on mechanical properties.
In general, increasing bioceramic content increases compressive modulus and yield stress to up until approximately
30% of the total weight of the system, and after such has
either negative or no effect on these properties.
The system may further provide for a mixture of bioceramics. For example, generally, nano-HA (NHA) demonstrated more benefit than micro-HA (MHA) at equivalent
concentrations, and NHA also provided the largest maximum compressive moduli and yield stresses. However, one
of the highest compressive moduli was observed at 30%
NHA content and with a mixture containing 15% MHA and
15% NHA, both of which provided similarly high properties. The compressive modulus of a 30% NHA mixture was
comparable to that of trabecular bone, making a 30% NHA

formulation a good mechanical match for the proposed
system. FIG. 1 shows a graph of modulus (A) and yield
stress (B) as a function of HA content.
Increasing hydrogel content increases viscosity almost
exponentially, while mechanical properties are unaffected
until 15% (by weight). By varying hydrogel content, a
thicker or thinner mixture can be formulated with little to no
mechanical implications. A more viscous injectable may be
suitable for larger defects or more osteoporotic bone, since
the paste will begin to solidify before it can escape the
injection site. A less viscous formulation is suitable for
collapsed bone or for regions of trabecular bone with lower
pore size, since the injection rate can be maximized to fill
dense trabecular networks. FIG. 2 shows representations of
viscosity and mechanical properties for scaffolds containing
various hydrogel microparticle content, formulated with
30% total NHA and the remainder of the weight composed
of 30% PLGA in NMP.
The injectable system of the present invention can fill
complex geometry, such as trabecular bone. FIG. 3 illustrates, using SAWBONES® open cell rigid polyurethane
foams made to mimic trabecular bone architecture, two
5x5x5 mm3 samples with and without the mixture injected,
demonstrating the space-filling capability of the mixture.
The samples receiving injections were immersed in buffer
for 3 days to ensure complete solidification of the PLGA.
Also included are graphs showing mechanical properties of
SAWBONES® injected with varying weight percentages of
NHA and MHA. Again, 30% NHA provided the most
benefit, and 15% NHA/15% MHA were comparable. Modulus is lower than pure scaffolds due to imperfect geometry
and the inferior mechanical properties of the Sawbones
themselves.
The system of the present invention can be adapted for a
variety of intraosseous treatments, with properties tuned to
fit the application. Both adult and pediatric avascular necrosis are targets for this treatment, and the drug content,
viscosity, and mechanical properties can be modified appropriately. In addition, compression fractures and bone cysts
are other applications for such a system where local
intraosseous delivery, space-filling, and solidification of a
drug delivery matrix are needed.
Those skilled in the art will appreciate that the bioceramic
particles can be mixed with the matrix either prior or post
cross-linking of the hydrogel. For example, bioceramics,
such as HA, can be mixed with a hydrogel, such as PBAE,
prior to cross-linking. Recent research has explored a new
composite ceramic-hydrogel microparticle instead ofhydrogel microparticles coated with ceramic, creating composite
ceramic-hydrogel sheets that can be easily ground into
microparticles without requiring additional ceramic as a
dispersant. This technique provide several advantages:
1. Composite particles retain virtually all therapeutic
agent (e.g. simvastatin) (99%) after a surface wash with
buffer, while previous particles retained approximately
50%. This can be attributed to absence of bioceramic
aggregates, which can loosely adsorb drug that ends up
washed off. Further, composite particles have a homogeneous distribution, e.g. of micro- and nanoscale HA
particles, throughout the particle volume (see FIG. 4),
so therapeutics should be retained within particles
rather than loosely bound to free HA.
2. Composite particles contain a relatively higher hydrogel content (33 w/w % vs 25 w/w %). This allows of
higher drug loading with equivalent hydrogel content,
which can either increase total drug dose or reduce the
viscosity of the injectable mixture at equivalent doses.
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3. The fabrication process of composite particles leads to
bioceramic particles uniformly distributed throughout
the composite particle volume, while the previous
technique resulted in bioceramic aggregates primarily
on the surface of particles, as well as bioceramic
aggregates unbound to any hydro gel. These micro structural differences are illustrated in the SEM images of
FIG. 4.
The examples described below demonstrate varying
loaded therapeutic agents within the system, as well as
mechanical properties and the overall texture and viscosity
to allow for injection. In general, increasing the bioceramic
concentration, such as increasing micro-HA (MHA) or
nano-HA (NHA) content, increases the system's compressive modulus and yield stress (generally, NHA provides
more benefit than MHA at equivalent concentrations, and
NHA also provides the largest maximum compressive
moduli and yield stresses). By varying the concentration of
hydrogel present, such as PBAE content, a thicker or thinner
mixture can be formulated with little to no mechanical
implications. The injectable mixture is also capable of filling
complex trabecular geometry. The system of the present
invention can be adapted for a variety of intraosseous
treatments, with properties tuned to fit the application. Both
adult and pediatric avascular necrosis are conditions that can
benefit from this system, and the drug content, viscosity, and
mechanical properties can be modified appropriately. In
addition, compression fractures and bone cysts are other
applications for such a system where local intraosseous
delivery, space-filling, and solidification of a drug delivery
matrix are needed.
The present invention provides for incorporating hydro gel
microparticles into a degradable matrix to provide several
new functions: mechanical support, porosity, space-filling,
and controlled co-delivery of antibiotics and osteogenic
drugs. Combining all these functions provides a more effective space-filling scaffold and offers improved release kinetics compared to existing systems used. Further, the system
of the present invention provides for acute antibiotic delivery accompanied by co-delivery of an antibiotic and an
osteogenic agent with improved effects on swelling, degradation, microarchitecture, and mechanical properties. (see,
e.g., bisected microCT reconstructions (FIGS. 5 and 8).
Hydrogel particle additives act as both porogens and drug
delivery vehicles within the solid degradable matrix. Hydrogel microparticles also influence macro- and microstructural
changes of the matrix as it degrades. Hydrogel microparticles further cause the degradable matrix to adopt a porous
network microarchitecture with no difference between surface or central pore sizes, because the homogeneous distribution of hydrogel microparticles act as a template for
uniform matrix precipitation. As set out in the examples, the
lattice-like matrix network of hydrogel-containing implants
provide sustained mechanical resilience even after the degradation period of the matrix had passed. The increased
porosity and accessible surface area ofhydrogel-containing
degradable matrices offers many advantages when considering matrix functions as a potential scaffold rather than
solely a drug delivery device.
The swelling of hydro gels provides for improved spacefilling and pocket retention of implants. As set forth in the
examples, even at an initial 3-day measurement, HMW-AH
samples had significantly higher interfacial strength than
controls, and this difference became even more pronounced
as the incubation period increased. AH hydrogels were
observed to swell beyond 200% of their initial mass within
2 days in PBS, and while this effect is may be muted due to

the physical constraint within the matrix, there is enough of
an effect to provide 4 to 10-fold higher interfacial strength
than controls.
A further benefit of the present invention lies in that a
scaffold that expands to fill its injection site as it solidifies is
less likely to cause irritation due to movement within the
pocket. Furthermore, more contact area between the implant
and the tissue means that the released drug has a shorter path
to enter the target tissue, and it has a smaller likelihood of
being washed away. This swelling-based, space-filling
approach is an alternative to other avenues that seek to
reduce detachment by improving the adhesion between the
polymer surface and surrounding tissue.
The present hydrogel-containing matrices demonstrated
improve pocket retention through a 15-day period as compared to other studies using more adhesive components,
which demonstrated increased bioadhesion in the first several hours following injection into a simulated pocket (Do M
P, Neut C, Delcourt E, Seixas Certo T, Siepmann J, Siepmann F. In situ forming implants for periodontitis treatment
with improved adhesive properties. Eur J Pharm Biopharm
2014 88(2): 342-50). As set forth in the examples, PLGA
deformed plastically and became stiffer under compression,
even at low strains and only 30 compression cycles, while
the modulus of HMW-AH samples remained unchanged,
demonstrating that hydrogel PBAE additives preserve elasticity. HMW-AH samples were less stiff and retained their
modulus throughout cyclic compression, demonstrating that
they are more suitable to withstand a dynamic mechanical
environment. The lack of change for both modulus and
resilience after cyclic loading with the present system provides for the development of more mechanically suitable
implants.
As described herein, in situ forming scaffolds according to
the present invention were characterized to determine their
mechanical properties, injectability, and microarchitecture.
Strength was increased approximately three-fold, while
compressive modulus was improved approximately 6-fold.
Scaffolds retained a uniformly porous microarchitecture,
and the bioceramic particles were distributed evenly
throughout the matrix. Injectability remained within clinically accepted standards. For example, ex vivo injections
into intact porcine femoral heads increased compressive
modulus of trabecular bone. The injectable scaffold of the
present invention thus offers mechanical reinforcement
coupled with drug delivery in a single injection for boneweakening conditions, such as osteonecrosis or osteoporosis.
An implant that acutely reinforces compromised bone,
controls drug release, and gradually degrades to allow
regeneration of native tissue can provide a comprehensive
treatment in a single injection. Scaffolds with material
properties similar to trabecular bone can aid load-bearing
while the drug delivery component of the scaffold exerts its
effect. It is important to consider these scaffolds as a means
for temporary augmentation that can acutely preserve bone
while treatment occurs, not as a replacement for healthy
bone tissue. Injectability is a unique concern for in situ
forming scaffolds, because both bioceramic and hydrogel
particle additives increase viscosity. Because prior injectable
degradable matrix systems were not intended for mechanical
support, and drug is usually mixed freely into the polymer
solution, viscosity has not been a limiting factor when
designing these systems. However, injectable bone cements
and fillers have encountered issues with injectability because
they are composed of a liquid phase containing high concentrations of suspended particles (Bohner M, Baroud G.
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Injectability of calcium phosphate pastes. Biomaterials
2005; 26(13):1553-1563; Alves H L, Santos LA, Bergmann
C P. Injectability evaluation of tricalcium phosphate bone
cement. J Mater Sci: Mater Med 2008; 19(5):2241-2246).
The scaffold of the present invention demonstrated the
capability of filling the bone tissue in all directions. Furthermore, injected bone tissue was significantly stronger and
stiffer than native tissue, suggesting that the filling that was
achieved is sufficient to greatly improve mechanical properties of trabecular bone.
Injectable scaffold mixtures are capable of being injected
through a standard bone biopsy needle, infiltrating trabecular bone, then solidifying to produce scaffolds with mechanical properties comparable to those of trabecular bone. This
injectable scaffold offers a treatment platform for ailments
requiring both drug delivery and mechanical reinforcement
of trabecular bone, and it has the advantage of being easily
injectable and fully resorbable.
The scaffold of the present invention provides a spacefilling system that can bypass spatial limitations of fixedform implants. Further, through investigating the present
invention, while drugs showed burst release when freely
mixed or encapsulated within gelatin microspheres, hydrogel particles allowed for more prolonged release. Scaffold
porosity further is important to allow new bone ingrowth,
and that the scaffolds will degrade over a period of months
allows for accommodation of tissue regeneration.
Bioceramic additives, such as hydroxyapatite, may
improve mechanical properties and bind to dianionic drugs,
such as bisphosphonates, to reduce initial burst. The addition
of these particle types can create a system suitable for
intraosseous injection due to the mechanical reinforcement
and delivery of both osteogenic and anti-resorptive treatments from a single injection. The ISI system containing
drug-loaded hydrogel microparticles exhibited significantly
reduced burst (81 % vs 39%) and extended release (95%
release by 28 days vs 10 days). Compressive modulus and
yield stress of cylindrical scaffolds increased up to 30 w/w
% bioceramic. Additives were demonstrated to improve both
release and mechanical properties of traditional ISis. Hydrogel microparticles and bioceramics reduced the initial burst
of drug release which may be suitable for intraosseous
injection where a treatment period of weeks is preferable but
rapid precipitation is required. Mechanical properties can be
controlled by varying bioceramic content and particle size
(e.g., nano may range from 5-10 nm to 100 nm, and micro
may range from 0.1-250 µm) and the system was capable of
space-filling throughout a trabecular bone-like sample and
improving its mechanical properties, which can acutely
salvage diseased or damaged bone while the drug release
component takes effect.
Bioceramics significantly increased the compressive
modulus and strength of the material. Ex vivo injections
resulted in good space-filling, and the injected material was
constrained by the articular and metaphyseal cartilage
boundaries. The addition of bioceramic particles enables in
situ forming implants to be used in a variety of orthopedic
applications because the mechanical properties can be
adjusted simply by varying the bioceramic concentration
and particle size. These composite scaffolds have a more
homogeneous pore structure, and the high accessibility of
these pores allows a greater surface area for potential cell
access and tissue contact. The addition of bioceramics also
allows these materials to be visualized during injection via
fluoroscopy to ensure the target site is receiving the treatment, and the material rapidly solidifies and is effectively
retained within the target tissue. Once solidified, the

implanted material improves the mechanical properties of
bone to prevent collapse of damaged or diseased tissue, and
the material degrades over the course of 6 weeks, which is
an appropriate period to allow drug release and bone repair.
The present invention also provides methods of using the
system. The present invention provides for contacting or
administering to a subject the system described herein. As
described above, the system can be administered by injection. Those skilled in the art will appreciate that the consistency, viscosity and overall make up of the applied system
will determine how the system is injected, affecting such
parameters as rate of injection, as well as gauge of needle.
Further parameters that can determine the rate of injection,
as well as the make of the applied system are the area of the
subject to receive the system. Those skilled in the art will
appreciate that certain applications will demand a slower
solidifying system, while others demand a faster solidifying
system. Further still, a subject may receive multiple injections in order to completely fill the area requiring application
of the system.
The present invention also provides methods for making
the system. As described herein, the components of the
system can be added together prior to injection within a
subject. Those skilled in the art will appreciate that the time
of adding the components altogether can be time sensitive as
the fully assembled system will start to solidify. For the
system described herein, solidification does not begin until
the mixture comes into contact with an aqueous phase.
Specifically, the system described herein offers the advantage of indefinite handling time, and the setting time only
begins post-injection. Further, as described herein the components or parts thereof, can be mixed together prior to cross
linking or post crosslinking. The components can be added
together such that of the final system: 30 w /w % ( +/-15%)
comprises the degradable matrix in solvent ( solvent provides
30-60 w/w % of the overall system); 30 w/w % ( +/-10%)
comprises bioceramic particles and 5-10 w/w % (+/-10%)
comprises hydrogel particles. For example, the system may
comprise a 30 w/w % PLGA solution in NMP, 30 w/w % HA
nanopowder and 3-20% w/w % PBAE microparticles.
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In situ forming implants are an attractive choice for
controlled drug release into a fixed location. Currently,
rapidly solidifying solvent exchange systems suffer from a
high initial burst, and sustained release behavior is tied to
polymer precipitation and degradation rate. The present
example investigated addition of hydroxyapatite (HA) and
drug-loaded poly(~-amino ester) (PBAE) microparticles to
in situ forming poly(lactic-co-glycolic acid) (PLGA)-based
systems to prolong release and reduce burst. PBAEs were
synthesized, imbibed with simvastatin (osteogenic) or clodronate (anti-resorptive), and then ground into microparticles. Microparticles were mixed with or without HA into a
PLGA solution, and the mixture was injected into buffer,
leading to precipitation and creating solid scaffolds with
embedded HA and PBAE microparticles. Simvastatin
release was prolonged through 30 days, and burst release
was reduced from 81 % to 39% when loaded into PBAE
microparticles. Clodronate burst was reduced from 49% to
32% after addition of HA filler, but release kinetics were
unaffected after loading into PBAE microparticles. Scaffold
dry mass remained unchanged through day 15, with a
pronounced increase in degradation rate after day 30, while
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wet scaffolds experienced a mass increase through day 25
due to swelling. Porosity and pore size changed throughout
degradation, likely due to a combination of swelling and
degradation. The system offers improved release kinetics,
multiple release profiles, and rapid solidification compared
to traditional in situ forming implants.
Materials
PBAE Polymer Synthesis
PBAE macromer was synthesized by reacting diethylene
glycol diacrylate and isobutylamine at a 1.2:1 diacrylate:
amine molar ratio at 85° C. for 16 hours. Macromer was
stored in an opaque vial under refrigeration until use. To
create crosslinked hydrogels from macromer, 1 wt/wt %
DMPA initiator dissolved in 50 wt/wt % ethanol was vortexed with macromer. The mixture was then pipetted
between two glass plates with Teflon spacers, sealed and
clamped, and then exposed to a UV flood source with an
intensity of 12 mW/cm2 for 5 minutes to form a crosslinked
hydrogel slab. These PBAE polymer slabs were washed
overnight in ethanol to remove unreacted monomer and
initiator, and then stored in a desiccator to remain dry until
use.
PBAE Particle Formation and Drug Loading
PBAE microparticles were formed by grinding dry PBAE
slabs with a mortar and pestle, with HA added during the
grinding process to coat particles and prevent aggregation.
HA content was preliminarily tested at 66 w/w % and 75
w/w % weight ratios, and 75% (50 v/v %) was chosen due
to ease of particle fabrication. PBAE particles were sieved
to less than 250 µm, and larger particles were re-ground until
all material was collected through the sieve. A Zeiss Evo
MA 10 scanning electron microscope (SEM) (Carl Zeiss,
Thornwood, N.Y.) at 4 kV accelerating voltage was used to
visualize particle morphology, and a Quantax energy-dispersive x-ray spectroscopy (EDS) detector was used for
elemental analysis. A series of 10 microscope images of HA
and PBAE particles were analyzed using freely available
ImageJ software to calculate mean particle size.
Simvastatin was either loaded into PBAE slabs prior to
particle formation (pre-loaded) or loaded directly into PBAE
microparticles (post-loaded), and each method was assessed
for loading efficiency as well as the percentage of drug that
was weakly bound to particle surface. FIG. 6A graphically
represents the processing method for creating PBAE
microparticles, as well as the differences between pre- and
post-loaded particles. Post-loaded particles were prepared
by dissolving simvastatin in ethanol at a concentration of
100 mg/mL and pipetting drug solution over particles at a
ratio of 2 µL per mg of particles. This ratio allowed particles
to swell without excess solution remaining, and expected
drug loads were calculated under the assumption that all
drug solution was imbibed by the microparticles. Particles
were lyophilized overnight, briefly re-ground and sieved to
break up aggregates, and stored in a vacuum chamber with
desiccant. Pre-loaded microparticles were prepared by
immersing PBAE slabs in simvastatin solution, allowing the
hydrogel to swell for 24 hours, and then removing the
hydrogel and lyophilizing overnight to evaporate ethanol.
Drug-loaded PBAE slabs were ground with 75 wt% HA into
particles and stored in a vacuum chamber with desiccant.
Predicted values for drug loading using the pre-loading
method were obtained by calculating swelling of PBAE in
solution based on mass increase and assuming drug was
homogeneously present in swollen hydrogels as well as
surrounding solution. The density and concentration of the
drug solution was then used to calculate expected drug
loading based on mass change of the PBAE samples. Clo-

dronate was loaded into separate batches of microparticles
using an identical pre-loading technique with a 50 mg/mL
clodronate solution in deionized water.
Measurement of Drug Loading into PBAE
Simvastatin loading into PBAE microparticles was measured by immersing drug-loaded particles in ethanol, vortexing, and allowing the particles to swell for 24 hours. The
mixtures containing ethanol and swollen PBAE microparticles were then centrifuged, and supernatants were analyzed
using HPLC to detect simvastatin, as described below.
Clodronate loading was measured with an identical technique using 50% ethanol, and was detected by absorbance as
described below. A mass balance indicated that all drug was
successfully removed from the particles during 24 hours of
immersion in ethanol for simvastatin or 50% ethanol solutions for clodronate, and subsequent immersions extracted
no additional drug. Loading efficiency was defined as the
ratio of the total mass of drug loaded into the particles to the
initial mass of drug exposed to the particles.
In addition to loading efficiency, the percentage of drug
present on the surface of particles was determined by
washing drug-loaded particles with 5 mL ethanol over a
filter to remove loosely surface-bound simvastatin or with 5
mL deionized water to remove loosely surface-bound clodronate. The remainder of drug present in the bulk of the
microparticles was extracted by immersing particles for 24
hours in ethanol for simvastatin or 50% ethanol for clodronate. Drug detected in the initial wash was deemed loosely
bound to the surface of particles, while drug detected after
the 24 hour soak was determined to be imbibed into the bulk
of the particles.
Formation of Injectable Scaffold System
PLGA was added to NMP and stirred overnight until fully
dissolved to create a 20 wt/wt % PLGA solution. Simvastatin-loaded PBAE microparticles pre-loaded using 100
mg/mL simvastatin were added at 5 wt % and mixed
homogeneously prior to injection. HA was also mixed
homogeneously prior to injection to bring the final mixture
to 30 wt % HA. Clodronate-loaded PBAE microparticles
pre-loaded with 50 mg/mL clodronate were added using an
identical technique. Samples without microparticles were
prepared by freely mixing 1 wt % simvastatin or clodronate
into 20% PLGA solution to simulate a traditional in situ
forming PLGA system. FIG. 6B illustrates the differences
between the proposed system and a traditional injectable
system. Simvastatin and clodronate were measured as
described below.
In Vitro Drug Release
The scaffold mixture was injected dropwise through a 16
gauge, blunt-tipped dispensing needle into PBS at 5%
wt/vol. Upon contacting PBS, surface PLGA immediately
began to precipitate, forming semi-spherical scaffolds
approximately 3 mm in diameter that sank to the bottom of
the vial. Samples were kept in an incubator at 37° C. on a
plate shaker for the duration of the study. Supernatant was
collected and replaced at each time point, and these samples
were preserved at 4° C. until analysis. Clodronate release
was measured for three loading conditions: freely mixed
clodronate without HA filler, freely mixed clodronate with
HA filler, and clodronate pre-loaded into PBAE microparticles with HA filler. Because PBAE microparticles were
fabricated with HA as a dispersing agent, drug release from
loaded particles was not investigated without HA filler.
Simvastatin release was measured for three loading conditions: freely mixed simvastatin without HA filler, freely
mixed simvastatin with HA filler, and simvastatin pre-loaded
into PBAE microparticles with HA filler.
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Measurement of Drug Concentrations
Simvastatin was measured on a Hitachi Primaide HPLC
system equipped with a C18 colunm using a mobile phase
composed of 70% acetonitrile and 30% water with 0.1 %
trifluoroacetic acid at a flow rate of 1 mL/min, and peaks
were observed at 240 nm. Clodronate from collected supernatants were measured using a Powerwave HT (Biotek;
Winooski, Vt., USA). In vitro release supernatant was
pipetted into a UV-grade 96-well plate (Greiner Bio-One,
Frickenhausen, Germany), and baseline absorbance was
measured at 240 nm. On its own, clodronate does not exhibit
a distinct absorption peak, so concentration was measured
by mixing supernatant with a solution of 1.5 mM copper
sulfate and 1.5 mM nitric acid at pH 2 to form a clodronatecopper complex that exhibits absorption at 240 nm. A pilot
experiment confirmed that HA did not significantly interfere
with clodronate readings in the working range.
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Characterization of Release Kinetics
Drug release from polymeric systems is often analyzed
using an adaptation of the Higuchi model by Peppas et al.,
widely known as the power law, to characterize release
kinetics (Siepmann J, Peppas NA. Modeling of drug release
from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews 2001;
48: 139-57):
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(1)

30

Here, M, is the mass of drug at time t, M is the total mass
of drug in the system,
35

represents Tractional release or drug at time t, k is a constant
encompassing scaffold and drug properties, and it is the
release exponent used to characterize drug release. In the
case of the spherical geometry (consistent with scaffolds
formed via dropwise injection), n=0.43 corresponds to pure
Fickian diffusion, n=0.85 corresponds to pure case II (polymer relaxation-based) transport, and values in between are
combinations of the two, termed anomalous transport (Siepmann J, Peppas NA. Modeling of drug release from delivery
systems based on hydroxypropyl methylcellulose (HPMC).
Advanced Drug Delivery Reviews 2001; 48:139-57). Plots
of
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versus log t were used to determine n for each drug. The
power law is applicable when
60
M,
M= < 0.6,
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so release data were truncated to below 60% cumulative
release when calculating n.

Mass Loss and Degradation
The injectable scaffold system was prepared as described
previously, using unloaded microparticles. Non-destructive
degradation analysis was performed on hydrated scaffolds in
order to observe the mass change of wet samples. Scaffolds
were injected dropwise into PBS and incubated at 37° C. on
a shaker for 80 days. Initial injected mass was recorded for
each scaffold. At intervals, scaffolds were removed from
PBS, gently blotted dry, and weighed. Destructive analysis
of dried samples was used to analyze scaffold dry mass
change. Scaffolds were injected dropwise into PBS and
incubated at 37° C. on a plate shaker until analysis. At each
time point, scaffolds were lyophilized for 24 hours, and dry
weight was measured. Lyophilized scaffolds were also
scanned using a Scanco MicroCT 40 (Scanco Medical,
Switzerland) at 55 kV and 145 mA with 6 µm voxel size. The
built in bone trabecular morphometry tool was used to create
3D reconstructions to visualize microarchitecture and quantify porosity and pore size at various time points during the
degradation process.
Statistical Analysis
All data are presented as mean±standard deviation.
Release data were analyzed in JMP 10 software, using
one-way analysis of variance (ANOVA) to determine differences between release curves followed by Tukey-Kramer
mean comparison tests as necessary. Comparisons between
individual pairs of samples for loading efficiencies were
performed using a student's two-tailed t-test. Differences
were considered significant for p<0.05.
Results
Drug Loading into PBAE Particles.
Drug loading into PBAE increased linearly with drug
solution concentration for simvastatin (FIG. 7A) and clodronate (FIGS. 7B and 7C). Clodronate became insoluble at
20 mg/mL in 50% ethanol, while the drug remained soluble
through 100 mg/mL in DI water. At 100 mg/mL clodronate,
however, it was observed that hydrogel would swell to a
greater degree and fracture upon handling, leading to high
variability between samples (FIG. 7C), so 50 mg/mL clodronate in DI water was used for future experiments. Simvastatin was loaded into gels or particles using a 100 mg/mL
solution in 100% ethanol.
HA possessed a mean particle diameter of 10 µm, while
the PBAE particles produced by grinding PBAE hydrogels
together with HA had a mean diameter of 68 µm. PBAE
microparticles exhibited a composite structure consisting of
spherical particles consistent with HA sizes embedded in an
amorphous material consistent with the hydrogel nature of
PBAE (FIG. SA). The spherical HA particles exhibited a
rough, granular surface morphology, compared to the
smooth PBAE component. EDS elemental mapping showed
calcium and phosphorous localized to the spherical particles
(FIG. SB). Point analysis of presumed HA and PBAE
regions indicated higher calcium and phosphorous levels in
spherical HA particles, and higher carbon and oxygen content in the PBAE region (FIG. SC). When these microparticles were immersed in a mixture of 20% PLGA solution in
NMP with 30 wt % HA added to simulate pre-injection
conditions, they underwent a 47% mass increase due to
swelling (FIG. SD), with a 28% increase occurring within 5
minutes.
Efficiency of incorporating simvastatin into post-loaded
particles ranged from 52% to 77% (FIG. 9B), and efficiency
ranged from 89% to 96% in pre-loaded particles (FIG. 9D).
A surface wash indicated that between 69% and 77% of
simvastatin was loosely surface-bound to post-loaded particles, with no differences between simvastatin concentrations (FIG. 9C). Using the pre-loading technique, a signifi-
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cantly lower amount (p<0.05), between 46% and 51 % of
simvastatin, was loosely surface-bound, again with no concentration dependence (FIG. 9A). Pre-loaded clodronate
yielded particles with 74% to 86% of drug loosely surfacebound (FIG. 9E). Clodronate loading efficiency ranged from
91 % to 97% at concentrations up to 50 mg/mL, and dropped
to 59% at 100 mg/mL.
In Vitro Release
Freely mixed simvastatin was 81% released within 1 day
and 95% released within 10 days, with no difference
between scaffolds prepared with or without HA (FIG. lOA).
In both cases, there was a gradual decrease in release rate as
fractional release (M/M=) reached 100%. Pre-loaded simvastatin microparticles mixed into the system reduced the 1
day burst to 39% (p<0.05), followed by sustained release of
1.3%/day for 30 days. The sustained release from day 1
through day 30 was roughly linear, with no appreciable
decrease in rate until completion of drug release.
Freely mixed clodronate prepared without HA exhibited a
49% burst within one day of release, while both freely mixed
and pre-loaded clodronate prepared with HA produced 32%
burst (p<0.05) (FIG. lOB). Freely mixed clodronate without
HA gradually released at a rate of0.6%/day through day 19,
while clodronate mixed with HA or pre-loaded into
microparticles released at 1.3%/day through day 19. By day
20, there was no difference in total clodronate release
between each curve. All clodronate release curves showed a
distinct increase in release rate to 3%/day at day 20 that
continued through day 31, after which nearly all drug was
released.
To characterize release kinetics, plots of

porous, and the denser regions near the edges of scaffolds
had become more porous. The dense regions appeared to
migrate towards one side of the scaffold by day 30, and by
day 35, scaffolds had significantly decreased in size, leaving
behind a uniformly porous pellet. After day 35, scaffolds
were too fragile to handle, and a representative sample of
residual material collected at day 40 was nonporous.
MicroCT morphometry revealed an increase in porosity
from 31 % through day 20 to 47% by day 30, followed by a
return to 30% at day 35 (FIG. 13A). Average pore size
ranged from 40 to 100 µm, except for samples at day 25,
which had average pore size of 231 µm (FIG. 13B).
Discussion
PBAE microparticles were successfully formed by cogrinding PBAE hydrogels with HA, forming individual
PBAE particles coated with multiple, smaller HA particles.
Elemental analysis confirmed that the smaller, spherical
coating consisted of HA, and the underlying particles were
hydrogel. Simvastatin pre-loaded into PBAE hydrogels
showed both higher loading efficiency and bulk imbibition
of drug, which are favorable conditions to prolong drug
release relative to freely mixed drug. Swelling data were
found to be an accurate predictor of drug loading into gels
at various concentrations, consistent with previous drug
loading results with hydrogels (Kim S, Bae Y, Okano T.
Hydrogels: Swelling, Drug Loading, and Release. Pharmaceutical Research 1992; 9:283-90). It was determined that
processing of particles does not appreciably affect simvastatin loading efficiency using the pre-loading technique
while still providing favorable imbibition ratios of surface to
bulk drug. A decrease in loading efficiency as well as a
higher percentage of simvastatin present loosely bound to
the surface of particles using a post-loading technique may
be attributable to the free HA powder used to coat the PBAE
particles absorbing a percentage of drug solution, preventing
its complete penetration into the hydrogel and resulting in a
majority of drug sequestered outside the hydro gel microparticles. The high levels of surface drug seen for clodronate
pre-loading may be due to the fact that the PBAE used in
these experiments swells to a significantly larger degree in
ethanol than in water (data not shown), allowing less penetration of drug into the bulk of the gels. Additionally,
clodronate was more favorably loaded into PBAEs in aqueous solutions rather than 50% ethanol solutions because its
solubility was limited. The swelling kinetics of PBAEs in
the injection mixture (30 wt % HA in 20% PLGA solution)
suggest that particles swell appreciably due to NMP exposure prior to injection, but the magnitude of swelling is
negligible compared to the amount observed in pure NMP
(47% at equilibrium vs. 470% in pure NMP). This difference
is due to the presence of PLGA, which dissolves readily in
NMP (Lambert W J, Peck K D. Development of an in situ
forming biodegradable poly-lactide-coglycolide system for
the controlled release of proteins. Journal of Controlled
Release 1995; 33:189-95) and prevents hydrogels from fully
swelling as they would in pure NMP. Additionally, the
particles may be immersed in PLGA solution for only a
matter of minutes before injection, so realistically, particles
may swell by only 23% if the system is injected 5 minutes
after addition of microparticles to the PLGA solution.
Simvastatin release was strongly affected by its loading
state. A comparison of release kinetics between injectable
systems loaded with freely mixed simvastatin and simvastatin-loaded PBAE microparticles indicated that burst
release can be significantly reduced and duration of release
can be significantly extended by loading simvastatin into
PBAE microparticles. Because simvastatin is soluble in
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vs log t were used to calculate n for pre-loaded simvastatin
and clodronate through the first day of release. After the first
day, release rates tended to be linear and were therefore
expressed as a daily release rate. For initial release during
the burst, simvastatin and clodronate release exhibited
n=0.47 and n=0.49, respectively.
Mass Loss and Degradation
Lyophilized scaffolds exhibited an initial mass loss of
50% in the first hour, followed by an additional gradual
decrease of 5% over the first day (FIG. llA). Mass fraction
remained unchanged at approximately 45% for 15 days,
followed by a linear decrease in mass at a rate of 0.2%/day
until day 50. Mass fraction did not change significantly after
day 50, ranging from 25% to 29% through day 80.
Lyophilized samples collected at day 40 and beyond were
primarily powder that crumbled upon handling.
Non-destructive mass change of wet scaffolds showed an
initial 12% decrease in mass over the first day, followed by
a linear increase of 1.4%/day over the next 14 days (FIG.
llB). At day 15, mass fraction became more variable as
some samples began to decrease in mass, while others
swelled through day 30. Linear mass loss was observed from
day 30 through day 55, when the remaining mass fraction
stabilized at 20% until day 80.
Qualitative assessment of microCT cutplanes roughly
bisecting samples revealed a uniformly porous microstructure through day 10 (FIG. 12). By day 15, denser regions had
developed in the middle and at the edges of scaffolds. By day
20, large macropores were present in the core of the scaffolds. At day 25, scaffold cores appeared more uniformly
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NMP, freely mixed drug presumably was dissolved in NMP
and the majority of it exited into the aqueous phase during
the solvent exchange process, resulting in a large burst
release. The residual 20% of simvastatin was released in a
sustained manner over the next 10 days, similar to previous
work on such systems using freely mixed drug (Tang Y,
Singh J. Controlled delivery of aspirin: effect of aspirin on
polymer degradation and in vitro release from PLGA based
phase sensitive systems. International Journal of Pharmaceutics 2008; 357:119-25; Bakhshi R, Vasheghani-Farahani
E, Mobedi H, Jamshidi A, Khakpour M. The effect of
additives on naltrexone hydrochloride release and solvent
removal rate from an injectable in situ forming PLGA
implant. Polymers for Advanced Technologies 2006;
17:354-9). PBAE microparticles experience some swelling
in the NMP-PLGA solution during the mixing stage prior to
injection, but burst is attenuated for pre-loaded PBAE
microparticles. The 39% burst release through day 1 using
pre-loaded particles may be attributable to loosely surfacebound simvastatin that was likely dissolved by NMP and
released during solvent exchange, similarly to freely-mixed
simvastatin. Because simvastatin was loaded into PBAE
with high efficiency, the release kinetics are likely a combination of the swelling, degradation, and diffusion of drug
through the PBAE material as well as the PLGA phase.
Clodronate release appeared to be unaffected by loading
state of the drug in PBAE microparticles, but it was instead
dependent on the presence of HA in the injection mixture.
This can be attributed to the formation of a complex between
the bisphosphonate drug and hydroxyapatite, specifically
between the two phosphonate groups of clodronate and the
divalent calcium cations present in HA crystals (Nancollas G
H, Tang R, Phipps R J, Henneman Z, Guide S, Wu W, et al.
Novel insights into actions of bisphosphonates on bone:
differences in interactions with hydroxyapatite. Bone 2006;
38:617-27). Freely mixed clodronate without HA filler was
49% released within 1 day, compared to 32% for both
compositions with HA. Because clodronate is insoluble in
NMP, this initial burst is likely due to free clodronate
suspended in the PLGA solution being dissolved by water
during solvent exchange. The increase in release rate
observed around day 20 corresponded to the maximum
swelling state of scaffolds, indicating that scaffolds had
begun to appreciably degrade and more water could enter
the system to promote more rapid clodronate dissolution.
Samples prepared with HA had a lower burst and higher
release rate between days 1 and 20 due to the clodronate
being initially retained in the system by complexation, after
which the drug was released diffusively from the solidified
system. Clodronate release kinetics are consistent with the
classic three-stage release profiles observed in rapidly-precipitating systems, in which an initial burst is followed by
slow diffusion, and then a more rapid swelling- or degradation-mediated release occurs (Fredenberg S, Wahlgren M,
Reslow M, Axelsson A. The mechanisms of drug release in
polylactic-co-glycolic acid)-based drug delivery systems-A review. International Journal of Pharmaceutics
2011; 415:34-52). Interestingly, the slow diffusion stage was
accelerated by the addition of HA, likely because the larger
amount of drug retained in the scaffold provided a higher
concentration gradient to drive diffusion.
The rapid precipitation implied by the initial burst of
clodronate and simvastatin as well as the early mass loss is
indicative of rapid NMP exchange, which demonstrates the
potential of the system for rapid solidification. Fast precipitation is favorable for quick delivery of NMP for an initial
osteogenic stimulus, and rapid formation of a solid drug

delivery depot may have advantages over gradually precipitating systems with persistent gel or liquid cores for days or
weeks after injection due to NMP retention (Bakhshi R,
Vasheghani-Farahani F, Mobedi H, Jamshidi A, Khakpour
M. The effect of additives on naltrexone hydrochloride
release and solvent removal rate from an injectable in situ
forming PLGA implant. Polymers for Advanced Technologies 2006; 17:354-9). Specifically, this has implications for
intraosseous injection, where the system can completely
precipitate within days while continuing to release drug over
a period of weeks to months. In systems with freely suspended or dissolved drug, precipitation rate strongly influences burst release (Graham PD, Brodbeck K J, McHughA
J. Phase inversion dynamics of PLGA solutions related to
drug delivery. Journal of Controlled Release 1999; 58:23345; Yewey G L, Duysen E G, Cox S M, Dunn R L. Delivery
of proteins from a controlled release injectable implant.
Pharmaceutical biotechnology 1997; 10:93-117), and the
addition of drug-loaded PBAE microparticles can allow for
prolonged release and decreased burst without prolonging
precipitation of the system. The rapid precipitation may also
allow filler particles, such as hydroxyapatite, to provide
mechanical support in future iterations of the system. After
the initial burst, pre-loaded simvastatin exhibited prolonged
delivery over the entire 30 day period. The lack of change in
simvastatin release kinetics upon addition of 30 wt % HA
was expected, because HA should not appreciably interact
with statins, which lack the phosphonate groups that provide
binding sites for the calcium in HA. The successful demonstration of sustained release of both hydrophilic and
hydrophobic small molecule drugs with reduced burst from
this system shows promise for new applications of in situ
forming PLGA systems where rapid precipitation is
required.
By fitting the power law to initial drug release, the release
exponent n can be used to classify the mechanism of drug
release from the system. For simvastatin, n of0.47 indicates
primarily Fickian diffusion based on the standard n values
for a spherical scaffold ofn=0.43 for pure Fickian diffusion
and n=0.85 for pure Case II transport. The slightly higher
release exponent compared to the pure Fickian value can be
attributed to several factors, including the swelling of the
PBAE hydrogel microparticles and minor swelling of the
surrounding PLGA matrix. Similarly, n of 0.49 for clodronate corresponds to primarily Fickian diffusion as well. Both
clodronate and simvastatin are therefore released via diffusive mechanisms prior to their sustained release, which
follows a more linear trend. This data supports the idea that
the burst was composed of a fraction of the loaded drug
dissolved or suspended in NMP, and the rapid solvent
exchange was likely responsible for the initial release. The
sustained release was likely a combination of diffusion,
erosion, and swelling-based mechanisms, and the superposition of these mechanisms produces release curves that are
most simply expressed in daily release rates. Because simvastatin is almost insoluble in water but highly soluble in
NMP, the larger burst compared to clodronate is unsurprising, as dissolved simvastatin may be transported out of the
scaffold during the solvent exchange phase. Future iterations
of the system may be able to further reduce burst by
reducing access of drug to the NMP phase to limit the initial
diffusive component of the system.
PLGA is a bulk-eroding material that degrades via hydrolysis of ester bonds, resulting in a progressive decrease in
molecular weight until monomeric or oligomeric species of
sufficiently low molecular weight are generated and cleared
when molecular weight drops to approximately 1.5 kDa
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(von Burkersroda F, Schedl L, GopferichA. Why degradable
polymers undergo surface erosion or bulk erosion. Biomaterials 2002; 23:4221-31; Kenley RA, Lee M 0, Mahoney
TR, Sanders L M. Poly(lactide-co-glycolide) decomposition
kinetics in vivo and in vitro. Macromolecules 1987;
20:2398-403). The in situ forming scaffold has the additional
property of a rapid precipitation event upon injection, and
due to the high aqueous miscibility of NMP, a rapid initial
dry mass loss was observed within the first hour following
injection as NMP entered the aqueous phase and the highly
hydrophobic PLGA precipitated. By 24 hours, 46% dry mass
remained, corresponding to the loss of the majority of the
NMP content that composed 54 wt % of the system. The
subsequent lack of dry mass change suggests that hydrolytic
degradation was unable to produce small enough molecular
weight species to be cleared into the surrounding aqueous
environment until day 15. After day 15, the linear decrease
in dry mass corresponded to clearance of degradation
byproducts until all PLGA was removed from the system.
The remaining 29% dry mass can be attributed to remaining
HA content that composed 30% of the original mass. For wet
scaffolds, the initial 12% decrease in wet mass throughout
the first day of degradation supports the replacement of
NMP with water due to precipitation of PLGA. The 20%
increase in wet mass over the following 14 days indicates
swelling of the PLGA matrix. Following this brief swelling,
individual sample behavior diverged as swelling reached a
maximum between 110-120% between days 20-30. The
linear decrease in mass was delayed compared to dry
samples because the small losses in polymer degradation
byproducts were offset by increased water content as the
system swelled. The lack of mass change beyond day 55 was
consistent with the complete clearance of PLGA observed in
dry mass studies, and the lower mass fraction remaining
(20% compared to 29%) was likely due to repeated handling
of samples during nondestructive measurements resulting in
small amounts of HA being resuspended and removed with
supernatant at each time point.
Based on microCT images, it was evident that scaffold
microarchitecture underwent dramatic changes throughout
the degradation process. The first indicator of change was
the development of denser regions in the core and near the
edges of scaffold by day 15, which may be attributable to the
cessation of NMP release and the hydrophobicity of PLGA
causing solid regions to condense together. At day 20, the
highest pore size was observed as large, closed macropores.
This phenomenon corresponds to the scaffolds at their
maximum swelling state based on wet mass, and was
accompanied by further densification of the core and edge
regions. At day 25, the core remained dense, but macropores
were no longer evident, and the edges of scaffolds were less
dense and more porous, which is consistent with reports of
PLGA of this molecular weight beginning to lose mass to
clearance after 3 weeks (Kenley RA, Lee M 0, Mahoney T
R, Sanders L M. Poly(lactide-co-glycolide) decomposition
kinetics in vivo and in vitro. Macromolecules 1987;
20:2398-403). At day 30, it is possible that enough polymer
had been lost to allow mobility of HA content through the
PLGA, which settled at the bottom of scaffolds during
incubation. By day 35, scaffold density and pore distribution
appeared more uniform, and scaffolds were noticeably
smaller in size due to further degradation of the highly
porous regions seen at day 30.
In situ forming PLGA systems have been popularized due
to their ease of use and unique ability to solidify at the point
of injection, forming a drug delivery depot in the tissue of
interest. However, because drug release from these systems

is highly dependent on solvent exchange and polymer chemistry (Graham P D, Brodbeck K J, McHugh A J. Phase
inversion dynamics of PLGA solutions related to drug
delivery. Journal of Controlled Release 1999; 58:233-45),
release of multiple agents with unique release profiles is
challenging. Additionally, low molecular weight drugs tend
to exit during the solvent exchange, resulting in high initial
burst (Parent M, Nouvel C, Koerber M, Sapin A, Maincent
P, Boudier A. PLGA in situ implants formed by phase
inversion: Critical physicochemical parameters to modulate
drug release. Journal of Controlled Release 2013; 172:292304). Multiple drug release platforms for small molecule
drugs, therefore, tend to be pre-formed scaffolds or injectable suspensions of micro- or nanoparticles (Biondi M,
Ungaro F, Quaglia F, Netti PA. Controlled drug delivery in
tissue engineering. Advanced Drug Delivery Reviews 2008;
60:229-42; Zhang L, Radovic-Moreno AF, Alexis F, Gu F
X, Basta PA, Bagalkot V, et al. Co-Delivery of Hydrophobic
and Hydrophilic Drugs from Nanoparticle-Aptamer Bioconjugates. ChemMedChem 2007; 2:1268-71; Sokolsky-Papkov M, Agashi K, Olaye A, Shakesheff K, Domb A J.
Polymer carriers for drug delivery in tissue engineering.
Advanced Drug Delivery Reviews 2007; 59:187-206; Zhou
T, Lewis H, Foster RE, Schwendeman S P. Development of
a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. Journal of Controlled Release 1998; 55:281-95). The addition of PBAE
microparticles to the in situ forming PLGA system combines
the ease of use of injectable systems, the controlled release
of microparticle systems, and the spatial control of solid
scaffolds. Even in a rapidly-solidifying system, PBAE
microparticles are capable of prolonging release of both
hydrophilic and hydrophobic drugs over a 30 day period
with significantly less burst than traditional injectable PLGA
systems using freely mixed drug.
Conclusions
An in situ hardening, PLGA-based system offers a unique
drug delivery platform due to its injectability and spacefilling properties, and the addition of drug-loaded microparticles introduces the possibility for tunable release profiles
for multiple pharmaceutical agents. In addition to the potential for multiple release profiles, the addition of drug-loaded
PBAE microparticles enables the sustained release ofwatersoluble, small molecule drugs, such as clodronate, as well as
lipophilic drugs, such as simvastatin, independent of PLGA
precipitation. The biodegradability of the system makes this
a favorable candidate for applications where a secondary
surgery to remove the depleted scaffold is undesirable or
impossible. Release kinetics can be multiphasic simply by
loading drug freely into the PLGA solution for burst release,
or into PBAE microparticles for sustained release with
reduced burst. This injectable scaffold provides the simplicity of a targeted injection with the utility of an implantable
drug delivery scaffold without compromising desirable
release kinetics.
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In situ forming scaffolds containing hydroxyapatite
micro- and nanoparticles were characterized to determine
their mechanical properties, injectability, and microarchitecture. Scaffolds were prepared with various concentrations of
hydroxyapatite, as well as poly(~-amino ester) microparticles that facilitate drug delivery. Strength was increased
three-fold, from 2 to 6 MPa, while compressive modulus
was improved 6-fold, from 24 to 141 MPa, via the addition
of 30% nano-hydroxyapatite, which provided greater ben-
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efits at equivalent concentrations compared to micro-hydroxyapatite. Scaffolds retained a uniformly porous microarchitecture, and hydroxyapatite particles were distributed
evenly throughout the PLGA phase. Injectability, determined by the force required to inject 0.5 mL of material
within 60 seconds, remained clinically acceptable at <50 N
at 30% w/w hydroxyapatite and up to 10% w/w PBAE
microparticles. Ex vivo injections into intact porcine femoral heads increased compressive modulus oftrabecular bone
from 81 to 180 MPa and strength from 3.5 to 5.9 MPa. This
injectable scaffold offers mechanical reinforcement coupled
with previously demonstrated drug delivery potential in a
single injection for bone-weakening conditions, such as
osteonecrosis or osteoporosis.
Synthesis of PBAE Microparticles
PBAE hydrogel slabs were synthesized as described previously (Anderson D G, Tweedie CA, Hossain N, Navarro
S M, Brey D M, Van Vliet K J, Langer R, Burdick J A. A
Combinatorial Library of Photocrosslinkable and Degradable Materials. Advanced Materials 2006; 18(19):26142618; Hawkins AM, Milbrandt TA, Puleo DA, Hilt J Z.
Synthesis and analysis of degradation, mechanical and toxicity properties of poly(~-amino ester) degradable hydrogels. Acta Biomaterialia 2011; 7(5):1956-1964). Briefly,
macromer was created by reacting diethylene glycol diacrylate with isobutylamine at 85° C. for 16 hours at a 1.2: 1
molar ratio. This macromer was then photopolymerized
between two glass plates with 1% w/w DMPA initiator and
a 1: 1 weight ratio of macromer to microparticulate hydroxyapatite (MHA) (Sigma-Aldrich, St. Louis, Mo., USA) to
form a PBAE hydrogel slab. PBAE hydrogels were previously loaded with drug for use as delivery vehicles, but were
left unloaded for these experiments. Microparticles were
formed by grinding PBAE slabs and sieving until all collected particles were 250 µm or less in size.
NHA Synthesis
Nanoparticulate HA (NHA; nGimat, Lexington, Ky.,
USA) was produced at nGimat LLC's facility in Lexington,
Ky., using a solution combustion process called NanoSpray
CombustionsM_ This scalable process is capable of producing synthetic bone minerals, such as HA, tricalcium phosphate (TCP), and amorphous calcium phosphate (ACP),
using cost-effective precursor materials. To produce NHA, a
calcium carboxylate precursor and an alkyl phosphate precursor of appropriate proportions were dissolved in an
organic solvent system, the solution was converted to an
ultrafine spray (referred to as a NanoSpray) using a device
called a Nanomiser®, and the spray was combusted under a
controlled atmosphere. The average particle size for the
NHA was <200 nm, as estimated by BET. X-ray diffraction
confirmed the presence of the HA phase (Ca5 (OH)(PO4 ) 3 ),
and X-ray fluorescence spectroscopy showed that the Ca:P
ratio was close to 5:3.
Formation of Cylindrical Scaffolds
PLGA (50:50 L:G, acid terminated, inherent viscosity
0.55-0.75 dL/g) was obtained from DURECT, Inc. (Birmingham, Ala., USA). All experiments used a polymer
solution of 30% w/w PLGA in NMP (Sigma-Aldrich, St.
Louis, Mo., USA). PBAE microparticles and MHA or NHA
were mixed homogeneously into the polymer solution using
a spatula. The scaffold mixture was loaded into a syringe and
injected through a 16 gauge needle into a cylindrical agarose
mold, where the system was allowed to solidify in phosphate-buffered saline (PBS). Scaffolds contained different
concentrations of MHA or NHA, ranging from 0% to 50%
w/w. All scaffolds contained 5% w/w PBAE microparticles
to mimic prior drug release study conditions, unless other-

wise indicated. PBS was replaced daily to prevent accumulation of NMP or low molecular weight species that were
cleared from the scaffolds.
Mechanical Properties of Cylindrical Scaffolds
All compression tests were performed using a Bose ELF
3300 mechanical testing instrument. Modulus was calculated as the slope of the initial linear region of the stressstrain curve (approximately the first 5-10% strain). Yield
stress was determined as the stress at which the stress-strain
curve became nonlinear. To first identify any strain ratedependence of mechanical properties, scaffolds prepared
with increasing MHA content were tested in unconstrained
compression to 50% strain at displacement rates of 0.006,
0.06, and 0.6 mm/s (strain rates of 0.001, 0.01, and 0.01 s- 1 ,
respectively). The contribution of PBAE microparticles to
mechanical properties was quantified by increasing PBAE
content from 1% to 15% w/w in scaffolds prepared with 30%
NHA.
To determine the effects ofNHA versus MHA on scaffold
properties, a comparison of mechanical properties for scaffolds containing different amounts of MHA and NHA was
performed at a displacement rate of 1 mm/min (0.0167
mm/s, or a strain rate of0.0028 s- 1 ) to 50% strain. Total HA
content ranged from O to 50% in intervals of 10%. Scaffolds
were prepared with either pure MHA, pure NHA, or different ratios of the two.
Injectability
To quantify injectability, scaffold mixtures contmmng
30% w/w NHAand 5, 10, or 15% w/w PBAE microparticles
were loaded into a 3 mL syringe affixed with a 1.5 inch, 16
gauge needle. The loaded syringe was suspended by its
flanges in a 15 mL centrifuge tube to collect the injected
mixture, with the end of the tube in contact with the load cell
and the plunger of the syringe in contact with the axial
mover. The plunger was subjected to a series of sustained
loads to simulate injection force, and the resulting displacement of the plunger was recorded. Injectability was quantified by plotting the time to inject 0.5 mL as a function of
the injection force. Rational limits of 60 second injection
time and 50 N injection force were set as the limits of
injectability based on consultation with an orthopedic surgeon.
Microarchitecture
Effects of HA on microarchitecture were analyzed by
preparing scaffolds with increasing NHA and MHA content,
as well as a variety of NHA/MHA mixtures totaling 30%
HA, lyophilizing these scaffolds after they had solidified in
PBS for 3 days, and then scanning them with a SCANCO
MicroCT 40 (SCANCO Medical AG, Switzerland) at 55 kV
and 145 mA and 6 µm voxel size. Microarchitecture was
quantified by porosity and material density. Scanning electron microscopy (SEM) was used to visualize micro- and
nanoarchitecture of scaffolds containing 30% w/w NHA.
Samples were freeze-fractured, coated with gold-palladium
alloy, and imaged with a Hitachi S-4300 scmming electron
microscope at 3 kV accelerating voltage.
Ex Vivo Scaffold Injections
Humeral heads were harvested from 10 week old male
piglets euthanized in a separate study, and were kept frozen
until use, without chemical fixation or removal of marrow.
Using a 16-gauge, 2.5-inch bone biopsy needle inserted
through the growth plate into the proximal humeral epiphysis, two humeral heads each received 3 mL ex vivo injections of30% NHA/5% PBAE scaffolds. Two humeral heads
were used as untreated controls. All humeral heads were
scanned using microCT prior to injection, immersed in PBS
for 5 days to allow scaffolds to fully solidify, and then
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scanned again to quantify scaffold infiltration. After 5 days
in PBS, a 3 mm diameter cylindrical punch was used to
remove tissue samples in the mediolateral direction, with the
punch approaching through the articular cartilage and penetrating through the growth plate, for a total of 7 samples
each for treatment and control groups. These cylindrical
samples were trimmed to 6 mm in length, using only
trabecular bone tissue between the growth plate and the
articular cartilage. All samples were stored in PBS and tested
the same day in unconstrained compression at a rate of 1
mm/min.
Results
Strain Rate and MHA Content
Scaffolds prepared with different MHA contents were
compressed at strain rates spanning three orders of magnitude. At strain rates of 0.001, 0.01, and 0.1 s- 1 (corresponding to displacement rates of 0.006, 0.06, and 0.6 mm/s),
modulus increased with MHA content (FIG. lA). The highest modulus increased from 64 to 82 to 96 MPa for each
respective strain rate, and overall, moduli ranged from 9 to
96 MPa. The lowest recorded modulus for any scaffold
containing HA was 29 MPa (10% MHA, 0.001 s- 1 ), while
scaffolds without any HA ranged from 9 to 30 MPa, increasing with strain rate. At 0.001 s-1, significant increases in
modulus occurred between 0-10% (p<0.01) and 30-50%
MHA (p<0.01 ). At 0.01 s- 1 , significant increases occurred
between 0-20% (p<0.05) and 20-50% MHA (p<0.0001). At
the highest strain rate of 0.1 s- 1 , modulus increased between
0-10% (p<0.01), 10-30% (p<0.001), and 30-40% MHA
(p<0.001). For equivalent scaffold formulations, average
modulus increased with increasing strain rate in every case,
and this trend was significant at 40% MHA between 0.01
and 0.1 s-1 (p<0.0001) and at 50% w/w MHA between
0.001 and 0.01 s-1 (p<0.05).
Yield stress followed a similar trend to modulus, however
the differences between scaffold formulations and between
strain rates were less pronounced (FIG. lB). Yield stresses
ranged from 1.1 to 7 MPa, and the highest yield stresses at
the three strain rates of0.001, 0.01, and 0.1 s- 1 were 4.4, 5,
and 7 MPa, respectively. Addition of 10% MHA to scaffolds
led to a threefold increase in yield stress at a strain rate of
0.001 s- 1 (from 1.1 to 3.3 MPa) and a twofold increase in
yield stress at 0.01 s- 1 (from 2 to 4.2 MPa), while 10% MHA
scaffolds experienced only a 13% increase (from 4.5 to 5.1
MPa) at a strain rate of 0.1 s-1. At 0.001 s-1, significant
increases in yield stress occurred between 0-10%
(p<0.0001) and 40-50% MHA (p<0.01). At 0.01 s-1, yield
stress significantly increased at 0-10% (p<0.0001) and
10-30% MHA (p<0.01 ). At the highest strain rate of 0.1 s- 1 ,
yield stress increased from 0-20% (p<0.05) and 20-50%
MHA (p<0.05). Similar to modulus, average yield stress for
equivalent scaffold formulations increased at every strain
rate. Increasing strain rate from 0.001 to 0.01 s- 1 led to an
increase in yield stress for 20% (p<0.001), 30% (p<0.01),
and 40% MHA scaffolds (p<0.001 ). Further increasing strain
rate from 0.01 to 0.1 s resulted in significantly increased
yield stress for 0% (p<0.0001), 30% (p<0.01), 40%
(p<0.01), and 50% MHA scaffolds (p<0.0001).
PBAE Content
Scaffolds prepared with 30 w/w % NHA and different
PBAE microparticle contents were compressed at 1 mm/min
(0.0028 s- 1 ). PBAE microparticle content did not significantly affect 30% NHA scaffold mechanical properties for
PBAE content ranging from 1 to 10 w/w %. Moduli ranging
from 96-120 MPa (FIG. 14A) and yield stresses from 4.3-4.9
MPa (FIG. 14B) were recorded in these PBAE content
ranges, with the highest modulus occurring at 10% PBAE

and the highest yield stress occurring at 1% PBAE. Increasing PBAE content from 10 to 15% led to a significant
decrease in modulus from 120 to 84 MPa (p<0.05). Average
yield stress of 15% PBAE scaffolds was 3.6 MPa, significantly lower than 1% PBAE scaffolds (p<0.05), which had
an average yield stress of 4.9 MPa. Samples became more
viscous and difficult to inject into molds as PBAE content
was increased. Beyond 15% PBAE, the mixture could still
be injected, but the scaffold began precipitating before it
could flow and fill the cylindrical mold, resulting in inconsistent morphology and unreliable mechanical properties.
Ratio of MHA to NHA
Scaffolds prepared with different amounts of MHA and
NHA were compressed at 1 mm/min (0.0028 s- 1 ). All
scaffolds generally increased in modulus up to 30% w/w
total HA content (FIG. 15A). In scaffolds prepared with only
MHA, a linear increase in modulus from 33 to 68 MPa was
observed from 10% through 30% MHA, although no significant difference was observed between groups. Modulus
was significantly different between 10% and 50% MHA
scaffolds (p<0.05). Scaffolds prepared with only NHA
exhibited a large and significant increase in modulus, from
53 to 141 MPa, between 20% and 30% NHA (p<0.0001).
Scaffolds prepared with equal amounts of NHA and MHA
possessed moduli similar to 30% NHA scaffolds, with 15:15,
20:20, and 25:25 NHA:MHA scaffolds all exhibiting moduli
between 128 and 151 MPa. Other scaffolds with similarly
high moduli included mixed NHA and MHA scaffolds with
total HA concentrations of 50% (10:40, 20:30, and 30:20
NHA:MHA). Notably, 20: 10 scaffolds exhibited significantly lower modulus than 15:15 and 30:0 NHA:MHA
scaffolds (p<0.0001). Scaffolds with 40% and 50% total had
the highest modulus at a 1: 1 NHA:MHA ratio, which
decreased when the NHA:MHA ratio was changed in either
direction.
Yield stress followed trends similar to modulus, however
the magnitude of these differences was lower (FIG. 3B). For
example, out of all scaffolds prepared with 30% total HA,
only 30:0 and 10:20 NHA:MHA samples were significantly
different (p<0.01). Scaffolds made with 40% pure MHA or
40% pure NHA had significantly lower yield stresses than
scaffolds prepared with a mixture of NHA and MHA
(p<0.01). At 50% total HA, scaffolds with 30% or higher
NHA content possessed lower yield stresses than scaffolds
composed of 25:25, 20:30, or 10:40 NHA:MHA (p<0.01).
Injectability
Injectable scaffold mixtures containing 5, 10, or 15 w/w
% PBAE microparticle content were injected through a 16
gauge, 1.5 inch needle with a series of increasing injection
forces. For each injection, the displacement of the plunger
initially increased rapidly due to compression of the rubber
plunger, the scaffold mixture, and any air bubbles, before
reaching a period oflinear displacement where flow rate was
constant, followed by a relaxation period as force was
removed (FIG. 16A). The linear portion of the displacement
curve was used to calculate displacement rate of the syringe
plunger, and the internal diameter of the syringe barrel was
used to calculate volumetric flow rate. The time required to
inject 0.5 mL of each mixture increased with increasing
PBAE content, and it decreased with increasing injection
force (FIG. 16B). Scaffolds were considered injectable if a
0.5 mL injection could be performed in 60 seconds or less,
which is indicated by the horizontal dashed line in FIG. 16B.
The 5% PBAE scaffolds were injectable for injection forces
greater than 16 N, 10% PBAE scaffolds became injectable
at 40 N, and 15% PBAE scaffolds became injectable at 75
N. The vertical dotted line at 50 Nin FIG. 16B indicates the
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limit for a reasonable injection force, beyond which sustained forces may be uncomfortable or cause fatigue for the
surgeon performing the procedure. For each scaffold composition, a logarithmic transformation of both injection force
and injection time resulted in the best fit.
Microarchitecture
Visualizing the microarchitecture of scaffolds prepared
with 30% w/w NHA and 5% w/w PBAE microparticles
revealed two distinct levels of porosity, with NHA and
PBAE particles trapped within the solid PLGA matrix.
Macroscopic pores on the order of 100 µm in diameter were
scattered throughout the scaffold (FIG. 17A), and the solid
PLGA matrix was primarily composed of a microporous,
honeycomb-like structure with pore sizes on the order of 10
µm (FIG. 17B). Elongated pores were observed at the
scaffold surface (FIG. 17C). HA nanoparticles, with spherical morphology and diameters on the order of 50 nm, were
present in the PLGA walls of the micropores (FIG. 17D).
These particles were densely packed in 30% w/w NHA
scaffolds.
MicroCT analysis allowed for quantification of microarchitectural parameters such as porosity and material density. Porosity generally decreased with increasing total HA
content, and this trend was most pronounced in samples
prepared with only MHA, which possessed porosities ranging from 2.4 to 48.1 %, while samples prepared with only
NHA had a porosity range of 13 to 22.5% (FIG. 18A).
MHA-only samples experienced a significant decrease in
porosity from 10-20% (p<0.001) and 30-40% (p<0.05), and
NHA-only samples had a significant decrease in porosity
from 10-30% (p<0.05). Samples with 30% total HA prepared with different mixtures of MHA and NHA did not
exhibit significantly different porosity from each other. At
equivalent weight percentages, samples prepared with pure
NHA had significantly lower porosity than those prepared
with MHA at 10% (p<0.0001), 20% (p<0.001), and 30%
(p<0.05), while porosity between the two groups was not
different at 40% and 50% w/w.
Material density increased with total HA content, and
scaffolds prepared with NHA experienced a larger increase
in density at each 10% increment of HA content (FIG. 18B).
MHA scaffolds exhibited significantly higher density than
NHA scaffolds at 10% (p<0.0001) and 20% (p<0.01), but
due to the smaller rate of increase, they exhibited lower
density than NHA scaffolds at 30%, 40%, and 50% w/w
(p<0.0001). The 30% HA scaffolds prepared with a mixture
of NHA and MHA had lower density at 10:20 NHA:MHA
formulations than scaffolds prepared with 15: 15 and 20: 10
NHA:MHA (p<0.0001).
Ex Vivo Scaffold Injections
During the injection of scaffolds into the humeral heads,
fluid was observed leaking out of bone near the growth plate,
indicating that the scaffold was displacing marrow and
filling the intertrabecular space. After the 3 mL injection into
two humeral heads, there was an average reduction in free
volume of 2.8 mL, corresponding to a 58% filling of the
intertrabecular volume (data not shown). A comparison of
cutplanes from a 3D reconstruction of the humeral heads
showed scaffold material distributed throughout the bone
volume, with small (sub-millimeter) regions of that were
unfilled. During removal of the cylindrical cores from
injected bones, it was observed that scaffold material was
constrained by the articular cartilage and growth plate.
Cylindrical samples of injected bone possessed a mean
compressive modulus of 180 MPa, compared to 81 MPa for
controls (p<0.001 ). Yield stress was also significantly higher

for injected bone, with a yield stress of 5.9 MPa for injected
samples compared to 3.5 MPa for controls (p<0.01).
Discussion
The general effects of HA additives on in situ forming
PLGA scaffolds were consistent with existing research on
preformed, implantable scaffolds (Huang Y X, Ren J, Chen
C, Ren T B, Zhou X Y. Preparation and Properties of
Poly(lactide-co-glycolide) (PLGA )INano-Hydroxyapatite
(NHA) Scaffolds by Thermally Induced Phase Separation
and Rabbit MSCs Culture on Scaffolds. Journal of Biomaterials Applications 2008; 22(5):409-432; Wei G, Ma P X.
Structure and properties of nano-hydroxyapatite/polymer
composite scaffolds for bone tissue engineering. Biomaterials 2004; 25(19):4749-4757; Verheyen CC PM, De Wijn
J R, Van Blitterswijk C A, De Groot K. Evaluation of
hydroxylapatite/poly(l-lactide) composites: Mechanical
behavior. Journal of Biomedical Materials Research 1992;
26(10):1277-1296; Guan L, Davies J E. Preparation and
characterization of a highly macroporous biodegradable
composite tissue engineering scaffold. Journal of Biomedical Materials Research Part A 2004; 71A(3):480-487), with
HA additives providing mechanical reinforcement, as evidenced by both compressive modulus and yield stress. As
HA content was increased beyond a certain point (generally
around 30% w/w, depending on the specific MHA and NHA
content), mechanical properties either plateaued, in the case
of MHA, or decreased, in the case of NHA. This effect can
be attributed to the total surface area of HA relative to the
volume of PLGA, which results in maximal scaffold
mechanical properties when sufficient PLGA is present to
bind HA together tightly without excess HA or PLGA. SEM
images of the 30% NHA scaffolds showed dense packing of
NHA nanoparticles embedded in the PLGA phase, which
may explain why further increasing NHA content was not
beneficial since particles were already in close proximity at
this loading. MHA scaffolds were mechanically inferior to
NHA at equivalent concentrations, likely due to the lower
surface area to volume ratio of MHA, which allowed fewer
PLGA:HA and HA:HA interfaces to form, and thus led to a
more loosely packed HA microstructure. Additionally, there
may exist a critical threshold for particle size, below which
significant mechanical benefits occur in a composite (Fu
S-Y, Feng X-Q, Lauke B, Mai Y-W. Effects of particle size,
particle/matrix interface adhesion and particle loading on
mechanical properties of particulate-polymer composites.
Composites Part B: Engineering 2008; 39(6):933-961).
Scaffolds with a higher NHA and MHA packing capacity
could potentially be created by increasing PLGA concentration in the PLGA/NMP solution (Guan L, Davies J E.
Preparation and characterization of a highly macroporous
biodegradable composite tissue engineering scaffold. Journal of Biomedical Materials Research Part A 2004; 71A(3):
480-487), however, this would also increase the viscosity of
the injectable mixture (Gad H, El-Nabarawi M, Abd ElHady S. Formulation and Evaluation of PLA and PLGA in
Situ Implants Containing Secnidazole and/or Doxycycline
for Treatment of Periodontitis. AAPS PharmSciTech 2008;
9(3):878-884).
An in situ forming HA-PLGA-PBAE implant offers severa! advantages over traditional orthopedic injectables, such
as poly(methyl methacrylate) (PMMA) bone cement. The
heat of free radical polymerization of PMMA in situ can lead
to protein denaturation and tissue necrosis (DiPisa Ja FauSih G S, Sih Gs Fau-Berman A T, Berman A T. The
temperature problem at the bone-acrylic cement interface of
the total hip replacement. Clinical Orthopaedics and Related
Research 1976; 121:95-98), whereas in situ forming PLGA
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scaffolds are formed via solvent exchange at ambient temperature. PMMA is not biodegradable, while PLGA
degrades hydrolytically over a time period dependent on its
chemical properties (Kenley RA, Lee M 0, Mahoney T R,
Sanders L M. Poly(lactide-co-glycolide) decomposition
kinetics in vivo and in vitro. Macromolecules 1987; 20(10):
2398-2403), Biodegradation is important for a drug delivery
scaffold embedded in a trabecular network, where removal
surgery is impossible and a permanent implant is not ideal.
Finally, the mechanical properties of PMMA are a better
match for cortical bone than a trabecular bone network,
while PLGA is a less stiff material that may be appropriately
augmented to match trabecular bone via addition of HA filler
(Saha S, Pal S. Mechanical properties of bone cement: A
review. Journal of Biomedical Materials Research 1984;
18(4):435-462; Rezwan K, Chen Q Z, Blaker J J, Boccaccini
AR. Biodegradable and bioactive porous polymer/inorganic
composite scaffolds for bone tissue engineering. Biomaterials 2006; 27(18):3413-3431). An implant that acutely
reinforces compromised bone, controls drug release, and
gradually degrades to allow regeneration of native tissue can
provide a comprehensive treatment in a single injection.
Interestingly, scaffolds prepared with equal amounts of
NHA and MHA tended to possess comparable mechanical
properties to scaffolds prepared with pure NHA or pure
MHA. This similarity may be due to the tight packing of
NHA in the spaces between MHA particles, resulting in
scaffolds that are effectively identical to tightly packed NHA
when compressed. Ultimately, the similarity between pure
NHA and equally mixed NHA/MHA scaffolds is probably
the result of two factors: 1) HA should be present at
sufficient concentrations so that load is primarily being
transmitted between tightly packed HA particles, and 2)
enough PLGA should be present so that it can bind all the
HA particles together. For a system intended for intraosseous injection, however, 30% NHA provides the highest
mechanical properties at the lowest total HA concentration,
and was therefore the most appealing formulation in terms
of injectability.
Native trabecular bone in human femoral heads has a
wide range of mechanical properties, with compressive
moduli ranging from 100-600 MPa and yield strength ranging from 1-9 MPa (Li B, Aspden R M. Composition and
mechanical properties of cancellous bone from the femoral
head of patients with osteoporosis or osteoarthritis. Journal
of Bone and Mineral Research 1997; 12(4):641-651; Schoenfeld C M, Lautenschlager E P, Meyer P R, Jr. Mechanical
properties of human cancellous bone in the femoral head.
Med & biol Engng 1974; 12(3):313-317). For conditions
that may be candidates for an injectable, intraosseous treatment, these values may be reduced by 24% (yield stress) and
20% (modulus) in osteoporotic patients (Li B, Aspden RM.
Composition and mechanical properties of cancellous bone
from the femoral head of patients with osteoporosis or
osteoarthritis. Journal of Bone and Mineral Research 1997;
12(4):641-651), or 50% (yield stress) and 72% (modulus) in
osteonecrosis patients (Schoenfeld C M, Lautenschlager E P,
Meyer P R, Jr. Mechanical properties of human cancellous
bone in the femoral head. Med & biol Engng 1974; 12(3):
313-317). Scaffolds with material properties similar to trabecular bone can aid load-bearing while the drug delivery
component of the scaffold exerts its effect (Rezwan K, Chen
Q Z, Blaker J J, Boccaccini AR. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone
tissue engineering. Biomaterials 2006; 27(18):3413-3431).
The average modulus of scaffolds prepared with 30% NHA
was 141 MPa, and the average yield stress was 6.2 MPa,

which are both within the range of trabecular bone. Although
in situ forming PLGA systems have not been extensively
investigated for their mechanical properties, the strength of
these scaffolds is 10-fold higher than a similar system
containing 33% a-tricalcium phosphate and PLGA of a
lower molecular weight (Schloegl W, Marschall V, Witting
MY, Volkmer E, Drosse I, Leicht U, Schieker M, Wiggenhorn M, Schaubhut F, Zahier S and others. Porosity and
mechanically optimized PLGA based in situ hardening systems. European Journal of Pharmaceutics and Biopharmaceutics 2012; 82(3):554-562). Furthermore, the yield stress
was on the higher end of healthy trabecular bone, so even if
scaffolds are slightly less stiff than the native bone tissue,
they can withstand similar stresses to healthy bone before
beginning to collapse. It is important to consider these
scaffolds as a means for temporary augmentation that can
acutely preserve bone while treatment occurs, not as a
replacement for healthy bone tissue. For this purpose, the
material properties of the 30% NHA system are sufficient.
Injectability is a unique concern for in situ forming
scaffolds, because both HA and PBAE particle additives
increase viscosity. Because prior injectable PLGA systems
were not intended for mechanical support, and drug is
usually mixed freely into the polymer solution, viscosity has
not been a limiting factor when designing these systems.
However, injectable bone cements and fillers have encountered issues with injectability because they are composed of
a liquid phase containing high concentrations of suspended
particles (Bohner M, Baroud G. Injectability of calcium
phosphate pastes. Biomaterials 2005; 26(13):1553-1563;
Alves H L, Santos LA, Bergmann C P. Injectability evaluation of tricalcium phosphate bone cement. J Mater Sci:
Mater Med 2008; 19(5):2241-2246). For example, decreasing the liquid to powder ratio increases the required injection
force and decreases the extruded fraction (Khairoun I,
Boltong M G, Driessens F C M, Planell J A. Some factors
controlling the injectability of calcium phosphate bone
cements. J Mater Sci: Mater Med 1998; 9(8):425-428;
Bohner M, Baroud G. Injectability of calcium phosphate
pastes. Biomaterials 2005; 26(13):1553-1563), which is
roughly analogous to increasing HA content in an injectable
PLGA system. Various additives have been investigated to
decrease the required injection force (Leroux L, Hatim Z,
Freche M, Lacout J L. Effects of various adjuvants (lactic
acid, glycerol, and chitosan) on the injectability of a calcium
phosphate cement. Bone 1999; 25(2, Supplement 1):31S34S). Injectability will likely be a persistent, nontrivial issue
for in situ forming PLGA systems containing mechanical
filler. Setting NHA content to a constant 30% and varying
PBAE microparticle content revealed that there is a clear
limit on PBAE microparticle content (and, therefore, drug
loading) beyond which the system cannot be injected without exceeding limits of injection force or injection time.
Longer-duration injections may be complicated by the precipitation of PLGA into a solid (Kempe S, Metz H, Mader
K. Do in situ forming PLG/NMP implants behave similar in
vitro and in vivo? A non-invasive and quantitative EPR
investigation on the mechanisms of the implant formation
process. Journal of Controlled Release 2008; 130(3):220225), leading to increased backpressure and a loss of injectability, while injections requiring large sustained force may
be uncomfortable for the surgeon performing the procedure.
The injection force limit may be circumvented by the use of
an injection gun, which would improve injection time and
greatly increase the injection force limit.
The space-filling and mechanical reinforcement potential
of an injectable system is likely to differ in situ from
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simulated tests, due to the presence of a constrained geometry filled with marrow and bordered by anatomical features
such as articular cartilage, cortical bone, and the growth
plate. The incomplete filling of free volume by the scaffold
suggests that the material establishes flow channels of low
resistance, resulting in small pockets of unfilled bone.
MicroCT images and cylindrical tissue samples, however,
show that these unfilled regions are distributed throughout
the bony network, and the scaffold was capable of filling the
bone tissue in all directions. Furthermore, injected bone
tissue was significantly stronger and stiffer than native
tissue, suggesting that the 58% filling that was achieved is
sufficient to greatly improve mechanical properties of trabecular bone.
Conclusions
The present study demonstrated the feasibility of an
injectable PLGA scaffold containing PBAE and HA particles
as a mechanically supportive, in situ forming scaffold.
Injectable scaffold mixtures are capable of being injected
through a standard bone biopsy needle, infiltrating trabecular bone, then solidifying to produce scaffolds with mechanical properties comparable to those of trabecular bone. This
injectable scaffold offers a promising treatment platform for
ailments requiring both drug delivery and mechanical reinforcement of trabecular bone, and it has the advantage of
being easily injectable and fully resorbable. This particular
system was optimized to accommodate NHA mechanical
filler and PBAE microparticles for drug delivery, with the
goal of an intraosseous injection into the femoral head. In
situ forming PLGA systems have traditionally been viewed
purely as drug delivery devices, but this study clearly
demonstrates the potential for a mechanical component to
these systems as well.

Thus, macromer made by reacting PEG400DA with isobutylamine for 48 hours was termed H6. A macromer containing a 2:1 molar ratio of diethylene glycol diacrylate:
PEG400DA was also created and will subsequently be
referred to as AH6. The ratio of total acrylate to amine
reactive groups was 1.2:1 for both macromers.
PBAE hydrogels were formed by adding 0.1% w/w
DMPA, dissolved in ethanol, to the macromer, pipetting this
mixture between two parallel glass plates, and exposing the
mixture to a 365 nm UV flood source for 5 minutes to
crosslink the macromer. The resulting hydrogels were
washed overnight in ethanol to remove residual DMPA and
unreacted monomers and then stored in a desiccator until
use.
PBAE microparticles were made by swelling PBAE
hydrogels in ethanol for 1 hour and then grinding them with
a mortar and pestle. The slurry was passed through a 250 µm
sieve using an ethanol wash, and any larger particles were
re-ground until 100% of the hydro gel was sieved. The
microparticle slurry was lyophilized, and the resulting
microparticles were stored in a desiccator.
Injectable Mixture Formulations
A PLGA solution was formed by dissolving 30% or 40%
w/w of either HMW or LMW PLGA in NMP overnight.
PBAE microparticles (H6, AH6, or a mixture of the two)
were added to the PLGA solution at 10% w/w and stirred
until the mixture was homogeneous. Simvastatin or doxycycline (2% w/w individually or 2% w/w each for codelivery) were added to the PLGA-PBAE-NMP suspension
and mixed thoroughly. Alternatively, doxycycline was preloaded into AH6 microparticles by swelling the microparticles with a 3 mg/mL doxycycline solution in acetone at a
ratio of 100 mg AH6 to 500 µL of solution. These swollen
particles were lyophilized for 24 hours, resulting in doxycycline pre-loaded into AH6 microparticles. Pre-loadedAH6
microparticles at 10% w/w in PLGA solutions were then
used in drug release studies. HMW formulations containing
simvastatin were tested first, and the most promising mixtures were used in subsequent tests with doxycycline and/or
LMW PLGA. Table 1 contains a list of all scaffold formulations that were examined for the drug release studies.

Example 3
Poly(~-amino ester) (PBAE) hydrogel microparticles
were incorporated into a PLGA matrix to provide several
new functions: mechanical support, porosity, space-filling,
and controlled co-delivery of antibiotics and osteogenic
drugs. PBAE-containing PLGA ISis are more effective
space-filling scaffolds and offer improved release kinetics
compared to existing ISis used to treat periodontitis.
Materials
Diethylene glycol diacrylate and poly(ethylene glycol)
400 diacrylate (PEG400DA) were bought from Polysciences, Inc. (Warrington, Pa.). High molecular weight
PLGA (HMW PLGA; 50:50 lactide:glycolide, 0.55-0.75
dL/g in hexafluoroisopropanol, carboxylate-terminated) and
low molecular weight PLGA (LMW PLGA; 50:50 lactide:
glycolide, 0.15-0.25 dL/g in hexafluoroisopropanol, carboxylate-terminated) were purchased from DURECT (Birmingham, Ala.). 2,2-Dimethoxy-2-phenylacetophenone
(DMPA), N-methyl-2-pyrrolidone (NMP), gelatin (from
porcine skin, type A), glutaraldehyde (25%, grade I), agarose, trifluoroacetic acid (TFA), doxycycline hyclate, and
glycine were obtained from Sigma Aldrich (St. Louis, Mo.).
Simvastatin was from Haorui Pharma-Chem (Edison, N.J.).
PBAE Hydrogel Preparation
PBAE macromer was synthesized by reacting diacrylate
with isobutylamine at 85° C. for 48 hours. Macromers were
named according to the classification system from Anderson
et al., in which the letter corresponds to a specific diacrylate
and the number corresponds to a specific amine (Anderson
D G, Tweedie CA, Hossain N, Navarro SM, Brey D M, Van
Vliet K J, et al. A combinatorial library of photocrosslinkable and degradable materials. Adv Mater 2006; 18:2614-8).
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Scaffold formulations investigated for drug release.
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Scaffold Name
HMW-AH
HMW-H
HMW-H/AH
50
BMW-Control
LMW-AH
LMW-Control
40LMW-AH
40LMW-Control

PLGA
HMW
HMW
HMW
HMW
LMW
LMW
LMW
LMW

PLGA% PBAE
30
30
30
30
30
30
40
40

Drugs

AH6
S/D/S
H6
s
AH6 + H6 s
None
SID
AH6
S/D/S
None
S/D/S
AH6
S/D/S
None
S/D/S

+ D/D(Pre)

+
+
+
+

D
D
D/D(Pre)
D/D(Pre)

55 Abbreviations:
S = simvastatin;
D = doxycycline.
(Pre) indicates drug was pre-loaded into PBAE microparticles, and
"+" indicates co-delivery of drugs from the same scaffold.

60

65

Microarchitecture and Mass Change
To observe changes in ISI mass and microarchitecture, the
following drug-free formulations were prepared: HMW-AH,
HMW-H, HMW-H/AH, HMW-Control, LMW-AH, and
LMW-Control (Table 1). In a 96-well plate, approximately
10 mg of injectable scaffold mixture were injected dropwise
from an 18-gauge needle into 300 µL of phosphate-buffered
saline (PBS), pH 7.4. The syringe was weighed after each
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injection to calculate the mass of each scaffold. PBS was
replaced daily to prevent buildup of degradation byproducts.
At each time point, 3 scaffolds from each group were
removed, dabbed dry, and weighed to measure the wet mass.
For HMW scaffolds, samples were collected at 1 and 5 days
following the injection and then every 5 days thereafter. For
LMW scaffolds, samples were collected at 1 and 2 days and
then every other day afterward. All collected ISis were
lyophilized for 24 hours and weighed again to determine dry
mass. HMW scaffolds were then scanned using a SCANCO
MicroCT 40 (SCANCO Medical AG, Switzerland) with
X-ray parameters of 55 kV and 145 mA, and a 6 µm voxel
size. A built-in bone trabecular morphometry analysis tool
was used to create 3-D reconstructions, and measurements
of porosity, mean pore size, and material density were
conducted. To quantify accessible volume and surface area,
simulated mercury intrusion porosimetry was run on the 3-D
reconstructions using an included script. At select time
points, samples were freeze-fractured, and a Hitachi S-4300
scanning electron microscope (SEM) at 4 kV accelerating
voltage was used to visualize the microarchitecture of scaffolds.
Mechanical Tests
All mechanical tests were performed with a Bose ELF
3300 system. Gelatin slabs (20%) measuring 8 mm thick
were crosslinked by overnight immersion in 5 mM glutaraldehyde. Unreacted aldehyde groups were quenched by
placing the crosslinked gelatin slabs in a 50 mM glycine
solution for 2 hours followed by serial washing with deionized water. Cylindrical samples (4 mm in diameter) were
punched out of the slabs, and their mechanical properties
were characterized by compressing these cylindrical
samples to 10% strain at a frequency of 1 Hz for 30 seconds
to mimic chewing conditions (Goktas S, Dmytryk J J,
Mcfetridge PS. Biomechanical behavior of oral soft tissues.
J Periodontol 2011; 82: 1178-86). The slabs containing cylindrical holes were used as molds to inject both HMW and
LMW Control and AH-containing scaffolds. After injection,
the molds were capped with 2% agarose slabs, lightly
clamped shut to prevent extrusion of material due to swelling, and immersed in PBS. After 3, 6, 9, 12, or 15 days, the
solidified samples within the molds were subjected to compression at a displacement rate of 0.5 mm/sec. The interfacial shear strength required for push-out was calculated by
dividing the maximum push-out force by the scaffold surface area in contact with the mold. Cylindrical scaffolds that
had been pushed out of their molds were tested for their
compressive properties under 1% strain triangular waves
applied at a frequency of 1 Hz for 60 seconds. The initial
modulus was determined from the first compression cycle,
and the equilibrium modulus was measured during the final
cycle. Resilience was calculated by integrating the linear
region of the stress-strain curve. These methods followed
protocols established to measure the mechanical properties
of gingival tissue (Goktas S, Dmytryk J J, Mcfetridge P S.
Biomechanical behavior of oral soft tissues. J Periodontal
2011; 82: 1178-86).
Drug Release
Approximately 100 mg of each mixture (Table 1) were
injected dropwise into 1 mL PBS, where the PLGA rapidly
solidified into droplet-shaped scaffolds. At each time point,
supernatant was entirely removed, stored in a refrigerator,
and replaced with fresh PBS. A Hitachi Primaide HPLC
system with a Kinetex C18 colunm was run isocratically at
1 mL/min with a mobile phase composed of 70% acetonitrile/30% water+0.1 % TFA to detect simvastatin at 240 nm.
Collected supernatant was mixed with ethanol at a 2: 1

supematant:ethanol ratio to dissolve any precipitated simvastatin prior to HPLC analysis. Doxycycline was assayed
using a mobile phase composed of 30% acetonitrile/70%
water+0.1 % TFA running at 1 mL/min and with detection at
350 nm.
Results
Mass Change
BMW-Controls exhibited little dry mass change through
the first 15 days of degradation, after which a linear decrease
in mass of 4.8%/day occurred through day 30 (FIG. 19A). A
significant (p<0.05) decrease in mass was observed at each
time point from day 20 and onward. Over the first 5 days, the
wet mass of these scaffolds decreased significantly (p<0.05)
at a rate of 9.4%/day and then increased slightly between
days 10 and 20, before gradually declining through day 35,
although none of these later changes was significant (FIG.
19B). Both HMW-AH and HMW-H/AH scaffolds exhibited
a small wet mass loss in the first day, followed by a relatively
linear 6.5%/day wet mass increase through day 30 to a
maximum of273% of original mass. At day 35, scaffolds fell
apart upon handling, and measurable mass decreased to 93%
of the initial value. HMW-H scaffolds had a larger wet mass
loss of37% (p<0.05) after 1 day, and between days 5 and 25,
an 8.6%/day mass increase occurred. A plateau was reached
between days 25 and 30 prior to a large decrease in mass at
day 35. After a 1-day dry mass loss of 12%, HMW-AH
scaffolds lost mass at a rate of 1.7%/day until day 10. Mass
loss resumed at day 15 and continued at a rate of0.87%/day
until day 30. HMW-H/AH scaffolds had a dry mass loss of
26% after day 1, and no significant mass change followed
through day 30. Similarly, HMW-H scaffolds exhibited a
large initial dry mass loss of 38% after 1 day, and no
significant subsequent mass loss occurred until day 30
(p<0.05).
LMW-Controls exhibited a gradual dry mass decrease to
89% after 8 days, after which the mass decreased linearly at
a rate of 3%/day through day 30 (FIG. 19C). LMW-Control
wet mass rapidly increased to 193% through the first 5 days,
then sharply declined and fluctuated around 150% through
day 16 (FIG. 19D). Beyond day 16, a linear mass loss of
7%/day occurred through day 30. LMW-AH scaffolds
decreased steadily in dry mass at a rate of 5%/day for the
first 8 days, followed by a brief plateau through 12 days, and
terminating with a linear mass loss of 2%/day through day
30. LMW-AH wet mass increased for the first 5 days and
plateaued, fluctuating around 150% through day 16. After
day 16, a mass loss of 7%/day occurred through day 30.
Microarchitecture
LMW samples were unable to be analyzed using microCT
due to their fragility following lyophilization, resulting in
structural collapse and unreliable scan data. The microarchitecture of BMW-Controls changed dramatically throughout
the first 15 days of degradation, leading to collapse, while
HMW ISis containing PBAE additives possessed a more
uniform pore structure and swelled visibly throughout the 15
day period (FIG. 20). After 1 day, BMW-Controls were
composed of a dense solid phase with large, homogeneously
distributed spherical pores with diameters on the order of0.5
mm to 2 mm. By day 5, some large pores remained in the
core of the scaffold, while most were present near the edges
and were oriented radially. By day 10, the radial pores were
more numerous, surrounding the dense core, and by day 15,
the scaffolds had collapsed. HMW-H scaffolds possessed a
uniformly porous microarchitecture by day 1, and there were
little microstructural changes until day 15, when noticeable
swelling had occurred. At day 15, BMW-Controls had a
17% increase over initial volume, while HMW-H, HMW-
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HI AH, and HMW-AH had increases of 33%, 84%, and 95%,
respectively. HMW-AH and HMW-H/AH scaffolds both
initially possessed porous networks with radiopaque regions
inside these pores, which is indicative of non-degraded
PBAE material (FIG. 2, arrows). By day 5, scaffolds were
noticeably swollen, and there was little evidence of nondegraded PBAE material, resulting in a uniformly porous
microarchitecture; swelling increased progressively through
day 15. None of the scaffolds containing PBAE additives
collapsed within the 15-day period.
HMW ISis generally increased in both porosity (FIG.
21A) and volume (FIG. 21B) as they degraded. Specifically,
BMW-Controls initially possessed 24% porosity, which
increased to a maximum of54% at day 10, and then declined
slightly to 46% by day 15. All PBAE-containing scaffolds
steadily increased throughout the 15-day period, with initial
porosities ranging from 42% (HMW-AH) to 55% (HMWH). All PBAE-containing ISis possessed significantly higher
porosities than BMW-Controls at all time points (p<0.001).
Among PBAE-containing ISis, only HMW-AH at day 1
differed significantly in porosity from others. Scaffold volume, normalized to initial mass, showed that BMW-Controls increased slightly in volume by day 5 before gradually
declining (FIG. 21B), and had significantly lower volume
than all PBAE groups throughout degradation (p<0.01).
HMW-H exhibited an initial decrease in scaffold volume
between days 1 and 5, followed by a linear increase beyond
the initial volume by day 15. Both HMW-AH and HMWH/AH generally increased in volume throughout the 15 day
period.
Accessible volume was measured for various simulated
penetrating sphere diameters ranging from 12 µm to 120 µm,
and the volume accessible by a 24 µm sphere was compared
between groups over 15 days (FIG. 21C). This diameter
approximates the size of the progenitor cells that may
migrate into these pores (Izumi K, Tobita T, Feinberg S E.
Isolation of human oral keratinocyte progenitor/stem cells. J
Dent Res 2007; 86:341-6; Lavenus S, Pilet P, Guicheux J,
Weiss P, Louam G, Layrolle P. Behaviour of mesenchymal
stem cells, fibroblasts and osteoblasts on smooth surfaces.
Acta Biomater 2011; 7:1525-34). At day 1, BMW-Control
and HMW-AH possessed significantly lower accessible volume than did HMW-H and HMW-AH samples (p<0.01). At
day 5 and beyond, all PBAE-containing ISis possessed
similar accessible volumes, which increased from 34-38% at
day 5 to 65-78% by day 15. From days 5 through 15,
controls had significantly lower accessible volume
(p<0.001). Accessible surface area was normalized to initial
scaffold mass, and measured using the same 24 µm penetrating sphere size (FIG. 21D). The trends for accessible
surface area were similar to accessible volume, with HMWControl and HMW-AH initially possessing significantly
lower values than HMW-H and HMW-AH (p<0.01). Controls remained significantly lower than all other groups for
each subsequent time point (p<0.001). HMW-AH increased
linearly in accessible surface area through day 15 before
plateauing, while both HMW-H/AH steadily increased in
accessible surface area throughout degradation. HMW-H
remained relatively unchanged between days 1-5 before
increasing linearly through day 15.
Mechanical Properties
The interfacial strength between ISI and cylindrical gelatin mold, as measured by maximum push-out force,
decreased over 15 days for BMW-Controls but increased
over the same period for HMW-AH (FIG. 22). For HMWControls, the interfacial strength was 1.2 kPa at 3 days, and
then decreased relatively linearly until it was significantly

reduced to 0.5 kPa by day 12 (p<0.05). The interfacial
strength of HMW-AH samples increased significantly from
4.7 kPa at day 3 to 8.8 kPa at day 6 (p<0.01), and the
interfacial strength continued to increase, although not significantly, to 11 kPa by day 15. At every time point, the
interfacial strength of HMW-AH significantly exceeded that
of BMW-Controls (p<0.001).
LMW samples exhibited a less dramatic difference
between AH and Control groups (FIG. 22). The interfacial
strength for LMW-Controls remained significantly higher
than BMW-Controls and lower than HMW-AH at all time
points (p<0.01), with interfacial strengths ranging from 2.7
to 5 kPa. LMW-AH interfacial strength increased from 5.2
kPa at day 3 to 8.7 kPa by day 9, and then decreased down
to 5.3 kPa by day 15. LMW-AH samples possessed significantly higher interfacial strength than did LMW-Controls for
the first 12 days tested (p<0.005), and the interface remained
similar to that for HMW-AH samples until days 12 and 14,
which were both significantly lower than corresponding
HMW-AH interfacial strengths (p<0.01). Both BMW-Control and HMW-AH cylindrical samples exhibited initial and
30-cycle compressive moduli that remained unchanged
through the first 9 days, followed by a decrease through day
15 (FIG. 23A). For BMW-Controls, initial modulus ranged
between 48 and 61 MPa through the first 12 days, and then
a significant decrease to 25 MPa occurred (p<0.01). Significant changes in HMW-AH samples were detected only
between day 15 and days 6 or 9 (p<0.05), and over the
15-day period, these moduli ranged from a minimum of 14
MPa at day 15 to 29 MPa at day 9. The 30-cycle modulus
of BMW-Controls did not change for the first 9 days, with
moduli ranging from 94 to 102 MPa. Significant decreases
occurred at day 12, to 58 MPa, and at day 15, to 17 MPa
(p<0.0001). Modulus ranged from 24 MPa at day 3 to 34
MPa by day 9, and then decreased significantly to 14 MPa
by day 15 (p<0.001). The ratio of the initial to the 30-cycle
modulus did not change significantly throughout the 15 day
period for HMW-AH samples, and it ranged from 0.95 at
day 15 to 1.16 at day 9 (FIG. 23B). For BMW-Controls, the
modulus ratio ranged from 1.67 to 1.88 over the first 9 days,
and then decreased significantly to 1.2 by day 12 and 0.7 by
day 15 (p<0.01).
Resilience of BMW-Controls and HMW-AH samples
increased between days 3 and 6 before declining through
day 15, and BMW-Controls exhibited the highest initial
resilience and the lowest 30-cycle resilience (FIG. 23C).
Resilience from the initial compression cycle of HMWControls increased significantly from 1 J/m3 at day 3 to 3.1
J/m3 at day 6 (p<0.0001 ), and then decreased significantly at
day 12 to 0.97 J/m3 (p<0.0001). The 30-cycle resilience
followed the same trend, with 0.35 J/m3 at day 3, which
increased significantly to 0.9 J/m3 by day 6, and then
dropped significantly to 0.25 J/m3 by day 12 (p<0.001).
Through the first 12 days, the ratio of the initial to the
30-cycle resilience ranged from 0.26 to 0.33, and a significant decrease occurred between days 9 and 15, down to 0.15
(p<0.05) (FIG. 23D). HMW-AH initial resilience increased
significantly between days 3 and 6, from 0.73 to 1.7 J/m 3
(p<0.001). The resilience did not change until day 15, when
a significant decrease occurred from 1.53 J/m 3 at day 9 to
0.79 J/m3 at day 15 (p<0.01). The 30-cycle modulus of
HMW-AH samples increased significantly from 0.46 J/m3 at
day 3 to 1.28 J/m3 at day 6 (p<0.0001), with subsequent
significant decreases at day 12, to 0.83 J/m3 (p<0.01), and at
day 15, to 0.52 J/m3 3 (p<0.05). The ratio of these two
resilience values for HMW-AH samples did not change
significantly throughout the 15 day period.
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LMW-Controls possessed uniformly higher ratios of initial to 30-cycle modulus at each time point compared to
LMW-AH, although this difference was significant at only
days 3 and 12 (p<0.05) (FIG. 23F). Similar to HMW
samples, LMW-AH samples exhibited an initial to 30-cycle
modulus ratio ranging from 0.94 to 1.13. While LMWControl initial modulus increased steadily from 3.2 to 8.6
MPa between days 3 and 12, LMW-AH initial modulus
fluctuated from 3.7 to 12 MPa, with a maximum at 9 days
and a minimum at 12 days, resulting in no clear trend (FIG.
23E). The initial resilience of both LMW-AH and LMWControl was highest at day 12, and in all cases, the 30-cycle
resilience was lower than the initial value for both LMWAH and LMW-Control (FIG. 23G). However, the ratio of
initial to 30-cycle resilience ofLMW-AH, ranging from 0.46
to 0.56, was significantly higher at every time point than the
same ratio for LMW-Control (p<0.05), which ranged from
0.15 to 0.33 (FIG. SH).
Drug Release
HMW scaffolds loaded with simvastatin released the drug
over 90 days, and scaffolds containing PBAE microparticles
produced release profiles with distinct regions of different
release rates (FIG. 24A). BMW-Controls exhibited a significantly higher 1-day burst of36% (p<0.001) compared to
all PBAE-containing groups, which had a burst of 6% or
less. BMW-Controls exhibited a declining daily release rate
over the course of 40 days, with residual simvastatin
released over the last 40 days as scaffolds completely
degraded. HMW-H exhibited a relatively linear release rate
of 1%/day through day 30, followed by a period of minimal
release through day 60. HMW-AH had a release rate of
2.8%/day for the first 13 days, followed by a period of
1%/day through day 30 and then 0.25%/day through day 50.
HMW-H/AH had release rates of 2.1 %/day through day 13,
1%/day through day 30, and then 0.2%/day through day 50.
Beyond day 60, the remaining drug was released through
day 90 as scaffolds completely degraded.
LMW scaffolds released simvastatin through 30 days, and
AH6 microparticle additives reduced the burst for each
formulation (FIG. 24B). LMW-Controls had 47% burst
followed by a roughly linear release rate of 2.1 %/day
through day 30. The burst was reduced to 21 % for 40LMWControls, after which the release rate steadily declined
through day 30. There was no difference in simvastatin
release kinetics between LMW-AH scaffolds containing
simvastatin alone or doxycycline and simvastatin together.
Both LMW-AH and 40LMW-AH scaffolds had no appreciable burst, and linear release rates ranged from 2.3 to
2.5%/day through days 24 and 26, respectively. After day 24
or 26, the release rate increased to 10%/day until all drug
was released.
Doxycycline exhibited similar release patterns from both
HMW (FIG. 25A) and LMW ISis (FIG. 25B), with no
difference observed between PBAE-containing scaffolds
and controls. Pre-loading doxycycline into PBAE microparticles resulted in a 1-day burst similar to controls, but with
significantly more drug released over the remainder of the
week. In all cases where the antibiotic was not pre-loaded
into AH6 microparticles, release plateaued within one or two
days, and drug was released incrementally for the remainder
of the monitored period. In all HMW ISis tested, release
plateaued at approximately 70% of total drug, and preloaded doxycycline released an additional 28% over the
following 6 days. For LMW ISis, the plateau ranged from
86-95% for 30% PLGA and from 63-74% in 40% PLGA.
ISis containing 40% LMW PLGA were tested with pre-

loaded doxycycline, and after an initial 63% burst, release
continued up to 87% by day 7.
Discussion
PBAE additives act as both porogens and drug delivery
vehicles within the solid. PLGA ISI matrix. As porogens, the
1-day mass loss of HMW-H and HMW-H/AH scaffolds
indicated complete degradation of H6, which has an
expected degradation time of 4-8 hours (Hawkins A M,
Milbrandt TA, Puleo D A, Hilt J Z. Synthesis and analysis
of degradation, mechanical and toxicity properties of poly
(~-amino ester) degradable hydrogels. Acta Biomater 2011;
7:1956-64), while both HMW-AH and LMW-AH scaffolds
exhibited a gradual mass loss through 10 days, which is
twice the 5 day in vitro degradation time of AH6 PBAEs
(Hawkins A M, Tolbert M E, Newton B, Milbrandt T A,
Puleo D A, Hilt J Z. Tuning biodegradable hydrogel properties via synthesis procedure. Polymer 2013; 54:4422-6).
The difference is probably due to the PLGA matrix both
limiting access of water to the embedded PBAE microparticles and physically preventing them from swelling, thus
slowing degradation (Clark A, Milbrandt TA, Hilt J Z, Puleo
DA. Mechanical properties and dual drug delivery application of poly(lactic-co-glycolic acid) scaffolds fabricated
with a poly(~-amino ester) porogen. Acta Biomater 2014;
10:2125-32; Hawkins AM, Milbrandt TA, Puleo DA, Hilt
J Z. Composite hydrogel scaffolds with controlled pore
opening via biodegradable hydrogel porogen degradation. J
Biomed Mater Res A 2014; 102:400-12). There is evidence
that PBAE swelling is restricted by comparing the microCT
cutplanes and implant volumes between groups, in which
HMW-H, which contains the most hydrophilic PBAE,
swelled more gradually and to a smaller degree than HMWAH and HMW-H/AH formulations. Theoretically, H6
should achieve greater maximum swelling than AH6, and
the maximum swelling point should occur at 4 and 36 hours,
respectively (Spencer D. Oswald physical and engineering
sciences second place: multiple macromer hydrogels for
multiphase drug release. Kaleidoscope 2014; 11:20).
HMW-H scaffolds likely delayed degradation of the PBAE
as well, however, the daily sampling frequency would not
detect a difference unless the degradation period of H6,
which typically degrades in 4-8 hours (Hawkins A M,
Milbrandt TA, Puleo D A, Hilt J Z. Synthesis and analysis
of degradation, mechanical and toxicity properties of poly
(~-amino ester) degradable hydrogels. Acta Biomater 2011;
7:1956-64), was prolonged beyond 24 hours. The failure of
BMW-Controls to swell beyond their initial mass suggests
that the loss ofNMP during precipitation exceeded the water
uptake of the scaffolds. Conversely, LMW-Controls were
capable of entrapping water in the core of the scaffolds due
to their less hydrophobic nature, and the rapid decrease in
wet mass after day 3 was caused by the fragile PLGA skin
rupturing, allowing the entrapped buffer to leak out. Interestingly, all HMW scaffolds containing PBAE microparticles swelled up to 250% of their original mass over a
period of30 days, while comparable LMW scaffolds swelled
to a maximum of 150%. Again, LMW scaffolds were prone
to rupture, which would allow water to escape, while the
HMW scaffolds remained structurally intact as they swelled
and therefore maintained a larger water capacity. Prior
research on similar systems containing porogens such as
sucrose or sodium chloride did not show such a dramatic
mass changes (Krebs M D, Sutter KA, Lin A S P, Guldberg
R E, Alsberg E. Injectable poly(lactic-co-glycolic) acid
scaffolds with in situ pore formation for tissue engineering.
Acta Biomater 2009; 5:2847-59), which suggests that the
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swelling behavior of PBAE hydrogel particles has a more
profound effect on water uptake and retention than traditional porogens.
PBAE microparticles also influence macro- and microstructural changes of ISis as they degrade. BMW-Controls
possessed surface-adjacent smaller pores and centrally-located macropores, which is typical of these implants because
PLGA at the surface tends to precipitate rapidly, while the
interior precipitates more gradually, allowing voids to
coalesce (Astaneh R, Erfan M, Moghimi H, Mobedi H.
Changes in morphology of in situ forming PLGA implant
prepared by different polymer molecular weight and its
effect on release behavior. J Phann Sci 2009; 98:135-45).
PBAE microparticles caused the ISis to adopt a porous
network microarchitecture with no difference between surface or central pore sizes, because the homogeneous distribution of hydrogel microparticles acted as a template for
uniform PLGA precipitation. This hypothesis is supported
by the rapid swelling and increase in accessible volume
observed in all PBAE-containing ISis. The lack of collapse
in HMW-AH, -H, or -H/AH implants implies that these
homogeneously distributed hydrogel particles also played a
role in structurally stabilizing the scaffolds. In BMW-Controls, the largest pores collapsed, whereas PBAE-containing
scaffolds, with their uniform microarchitectures, were able
to distribute stresses throughout the PLGA matrix and avoid
collapse. It has been previously demonstrated that varying
the size and distribution of pores can dramatically alter
mechanical properties of materials (Li H, Oppenheimer S M,
Stupp S I, Dunand D C, Brinson L C. Effects of pore
morphology and bone ingrowth on mechanical properties of
microporous titanium as an orthopaedic implant material.
Mater Trans 2004; 45:1124-31; Yu H, Matthew H W,
Wooley P H, Yang S-Y. Effect of porosity and pore size on
microstructures and mechanical properties of poly-E-caprolactone-hydroxyapatite composites. J Biomed Mater Res B
Appl Biomater 2008; 866:541-7). The lattice-like PLGA
network of PBAE-containing implants may also help
explain the sustained mechanical resilience observed for
HMW-AH implants even after the degradation period of the
PBAE had passed. The increased porosity and accessible
surface area of PBAE-containing ISis offers many advantages when considering PLGA ISis as potential scaffolds
rather than simply drug delivery devices. In pre-formed
PLGA scaffolds, larger accessible volume and surface area
provide more opportunity for tissue ingrowth, and it is
anticipated that PLGA ISis will behave similarly in future
cell culture or in vivo testing.
A persistent issue with antibiotic-releasing implants in
periodontal applications is that the implant is not secure
inside the periodontal pocket, which can lead to small pieces
being dislodged as the implant moves within the space
(Anderson H H. Treatment of chronic periodontitis: a sitespecific fiber placement technique. Pract Periodontics Aesthet Dent 1996; 8:565-70). Here, push-out forces were used
to measure the interfacial strength between the implant
surface and a simulated tissue pocket. The opposing trends
observed in push-out force for BMW-Control compared to
HMW-AH samples indicate that swelling of AH hydrogels
can improve space-filling and pocket retention of implants.
Even at the initial 3-day measurement, HMW-AH samples
had significantly higher interfacial strength than controls,
and this difference became even more pronounced as the
incubation period increased. Although HMW PLGA does
swell to a small degree as it degrades, this behavior is offset
by the shrinkage of the implant during the precipitation
phase, and the net result is that the interfacial strength

remains negligible. On the other hand, AH hydrogels were
observed to swell beyond 200% of their initial mass within
2 days in PBS (data not shown), and although this effect is
probably muted due to the physical constraint within the
PLGA matrix, there is enough of an effect to provide 4 to
10-fold higher interfacial strength than controls. Preliminary
studies also showed no measurable adhesion between the
gelatin surface and the implants (data not shown), so any
differences in interfacial strength should be solely a result of
the superior space-filling due to swelling of HMW-AH
implants. LMW-AH scaffolds exhibited a similar benefit
compared to LMW-Controls, although this difference was
less pronounced due to the natural swelling behavior of
LMW-Controls, which increased interfacial strength, and
the rapid degradation of material, which caused both LMWControls and LMW-AH to decrease in strength over the 15
day period. A scaffold that expands to fill its injection site as
it solidifies is less likely to cause irritation due to movement
within the pocket. Furthermore, more contact area between
the implant and the tissue means that the released drug has
a shorter path to enter the gingival tissue, and it has a smaller
likelihood of being washed away due to exchange in the
crevicular fluid. Little information is available on the magnitude of stresses experienced within gingival soft tissue, but
the periodontal ligament is the soft tissue responsible for
transmitting chewing force between the tooth and the underlying alveolar bone (Andersen K L, Pedersen E H, Melsen
B. Material parameters and stress profiles within the periodontal ligament. Am J Orthod Dentofacial Orthop 1991;
99:427-40; Beertsen W, McCulloch CA G, Sodek J. The
periodontal ligament: a unique, multifunctional connective
tissue. Periodontal 2000 1997; 13:20-40). Measurements of
stress in oral mucosa! tissues under typical bite forces of
denture wearers suggested that these tissues experience
compressive stresses ranging from 5 to 40 kPa during
chewing (Sawada A, Wakabayashi N, Ona M, Suzuki T.
Viscoelasticity of human oral mucosa: implications for
masticatory biomechanics. J Dent Res 2011; 90:590-5).
According to these values, HMW-AH ISis have initial
interfacial strengths within that range, and within 6 days the
interfacial strength exceeds the stress generated by a soft
bite. BMW-Controls at every time point possessed interfacial strengths 1-2 orders of magnitude lower. These data
suggest that patients receiving HMW-AH ISis may be able
to chew food shortly after receiving treatment without
danger of loosening the implant, while controls, which
approximate clinically available treatments, are more easily
loosened and dislodged. This swelling-based, space-filling
approach is an alternative to other avenues that seek to
reduce detachment by improving the adhesion between the
polymer surface and surrounding tissue. In a separate study
using a more adhesive components, increased bioadhesion
was observed in the first several hours following injection
into a simulated pocket (Do MP, Neut C, Delcourt E, Seixas
Certo T, Siepmann J, Siepmann F. In situ forming implants
for periodontitis treatment with improved adhesive properties. Eur J Pharm Biopharm 2014:[Epub ahead of print]),
whereas the present PBAE-containing ISis were demonstrated to improve pocket retention through a 15-day period.
An interesting approach for future studies may be to incorporate both bioadhesive and swelling additives in order to
provide acute attachment followed by prolonged spacefilling.
Although these periodontal ISis are not designed as
load-bearing structures, they are subject to stresses, primarily due to chewing, which typically occurs at frequencies
between 0.1 and 1 Hz in humans (Tanaka E, Yamana E,
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Dalla-Bona DA, Watanabe M, Inubushi T, Shirakura M, et
al. Dynamic compressive properties of the mandibular condylar cartilage. J Dent Res 2006; 85:571-5). The gelatin
molds used in push-out studies had similar compressive
modulus compared to gingival tissues in order to simulate a
periodontal pocket (Goktas S, Dmytryk J J, Mcfetridge PS.
Biomechanical behavior of oral soft tissues. J Periodontal
2011; 82: 1178-86). It has been proposed that less stiff
implants may reduce irritation due to the presence of material within the periodontal pocket (Qin Y, Yuan M, Li L, Li
W, Xue J. Formulation and evaluation of in situ forming
PLA implant containing tinidazole for the treatment of
periodontitis. J Biomed Mater Res B Appl Biomater 2012;
l00B:2197-202). PLGA deformed plastically and became
stiffer under compression, even at low strains and only 30
compression cycles, while the modulus of HMW-AH
samples remained unchanged, indicating that PBAE additives preserve elasticity. In the commercially available Atridox® system, a dressing or adhesive is used to keep the
implant in place, but there is also the concern that repeated
compression cycles can cause the implants to break apart,
allowing pieces of material to cause local irritation or escape
the periodontal pocket (Drisko C H. The use of locallydelivered doxycycline in the treatment of periodontitis.
Clinical results*. J Clin Periodontol 1998; 25:947-52; Karimbux N. Clinical cases in periodontics. Chichester, West
Sussex, UK: Wiley-Blackwell; 2012). Therefore, flossing
and brushing are discouraged for up to a week following
implantation, and patients are told to expect small pieces of
material to break off (Drisko C H. The use of locallydelivered doxycycline in the treatment of periodontitis.
Clinical results*. J Clin Periodontal 1998; 25:947-52).
Although neither control nor PBAE-containing ISis broke
apart during the timeframe or compression cycles observed,
the 30-cycle modulus of BMW-Controls was reduced dramatically between 9 and 15 days, and this difference would
likely become more pronounced as time or compression
cycles increased. HMW-AH samples were less stiff and
retained their modulus throughout cyclic compression,
which suggests they are more suitable to withstand the
dynamic mechanical environment of the periodontal tissue.
BMW-Controls and LMW-Controls were more resilient
during the initial compression cycle, yet they were consistently less resilient than corresponding AH-containing
implants after 30 cycles, indicating that the PBAE hydrogel
component helps preserve resilience. The lack of change for
both modulus and resilience after cyclic loading is promising for the development of more mechanically suitable
implants for the periodontal pocket. Dynamic mechanical
analysis is required to assess viscoelastic properties for full
lifespan of the implant, but this short-term cyclic compression data suggests that the addition of only 10% hydro gel
particles can greatly improve the durability of these
implants. As mentioned previously, the addition of PBAE
microparticles led to a lattice-like PLGA microarchitecture,
which should theoretically provide more resilience than the
heterogeneous structure of the controls because there are no
macropores, which appear to be the source of collapse in
controls. Oral soft tissues have compressive moduli ranging
from 0.2 to 8 MP, and typical dental materials used to fill
these soft tissues after extractions or other procedures have
moduli on the order of 1-20 MPa, which are both similar to
the compressive properties of ISis developed here.
Simvastatin release kinetics from both HMW and LMW
ISis were highly dependent on PBAE microparticle content.
The larger burst in controls can be attributed to simvastatin
dissolved in the NMP phase being rapidly lost during solvent

exchange, which has been previously reported (Fisher P D,
Palomino P, Milbrandt TA, Hilt J Z, Puleo D A. Improved
small molecule drug release from in situ forming poly
(lactic-co-glycolic acid) scaffolds incorporating poly(betaamino ester) and hydroxyapatite microparticles. J Biomater
Sci Polym Ed 2014; 25:1174-93). Because these PBAEs
swell in many organic solvents, such as NMP, acetone, and
ethanol, PBAE microparticles become swollen with NMP
and simvastatin during the mixing phase prior to injection.
Simvastatin, which is freely soluble in NMP, is preferentially taken up by PBAEs, which act as NMP sponges, while
NMP-insoluble drugs such as doxycycline remain in the
PLGA phase outside the swollen particles (data not shown).
These swollen microparticles act as an additional diffusive
barrier to reduce initial burst of simvastatin, and once the
initial hardening of the scaffold surface has occurred, simvastatin release is governed by both diffusion and PBAE
degradation. The degradation profile of AH6 microparticles
is reflected in the accelerated release rate from AH- and
H/AH-containing scaffolds through day 13. The release
profile for HMW-H/AH ISis closely approximates the average of the HMW-H and HMW-AH curves, which suggests
that the two hydrogels contribute independently to simvastatin release kinetics, and the results of their contributions
are additive. Simvastatin release kinetics were more strongly
affected by PBAE microparticle content in 30% LMW
PLGA scaffolds than in 40% LMW PLGA scaffolds, and this
difference is attributable to multiple factors. First, the higher
PLGA content formulation is more viscous, which allows
more rapid formation of a protective "skin" that slows
solvent exchange and thus burst release. Second, 40% LMW
ISis contain more PLGA for equivalent injected masses
when compared to 30% LMW ISis, which provides more
polymer volume to entrap simvastatin, further limiting burst.
Interestingly, AH6 degradation did not appear to accelerate
simvastatin release in LMW scaffolds as dramatically as it
did in HMW scaffolds for the first 10 days. This may be due
to the faster degradation time and relatively lower hydrophobicity of LMW PLGA, which allows faster simvastatin
release from the PLGA phase and masks the contribution of
AH6-mediated release.
Release kinetics of freely-mixed doxycycline from HMW
and LMW ISis were unaffected by the addition of PBAE
microparticles, however pre-loading doxycycline into AH6
microparticles provided a measure of control. The lack of
additional doxycycline release after the initial burst in freely
mixed cases is probably due to the entrapment of remaining
drug in the PLGA phase, and because doxycycline is substantially more hydrophilic than simvastatin, it has low
mobility through the hydrophobic PLGA matrix. This plateau effect is undesirable for antibiotic delivery, because
bacteria surviving the initial burst will be free to re-colonize.
By pre-loading doxycycline into AH6 PBAE microparticles,
the initial burst was followed by continuous release of
remaining drug through 1 week, which is consistent with
systemic doxycycline regimens of 1 week following scaling
and root planing.
Conclusions
PLGA ISis formulated with PBAE microparticle additives provide multiple advantages over existing periodontal
ISis. These composite ISis are more resilient and are
retained more firmly in simulated gingival tissue than PLGA
alone, so there will be a lower risk of the implant deforming,
loosening, and premature fragmentation, which is a concern
with existing systems. Additionally, PBAE microparticles
offer a secondary means of controlling drug release kinetics,
and multiple drugs with independent release profiles can be
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delivered, instead of the single-drug systems that are currently available. Future studies will focus on the potential of
these PBAE-containing ISis to act as scaffolds for tissue
regeneration, because the high porosity and open pore
network is suitable for tissue ingrowth.
The foregoing descriptions of various embodiments provide illustration of the inventive concepts. The descriptions
are not intended to be exhaustive or to limit the disclosed
invention to the precise form disclosed. Modifications or
variations are also possible in light of the above teachings.
The embodiments described above were chosen to provide
the best application to thereby enable one of ordinary skill
in the art to utilize the inventions in various embodiments
and with various modifications as are suited to the particular
use contemplated. All such modifications and variations are
within the scope of the invention. All publications, patents
and patent applications referenced herein are to be each
individually considered to be incorporated by reference in
their entirety.
What is claimed:
1. An injectable system for assisting in osseous tissue
repair, the system comprising a degradable matrix and
composite microparticles in a solvent, the degradable matrix
being selected from the group consisting of PLGA, poly
(lactic acid) and poly( E-caprolactone) and the solvent being
selected from the group consisting of N-methyl-2-pyrrolidone, dimethyl sulfoxide, ethyl acetate, ethyl benzoate, and
triacetin, wherein the composite microparticles comprise
cross-linked poly(~-amino ester) (PBAE) microparticles
embedded with a ceramic, the ceramic being embedded by
dry grinding and the ceramic being selected from the group
consisting of hydroxyapatite (HA), brushite, calcium polyphosphate, ~-tricalcium phosphate, and monetite, and further wherein the system solidifies in situ.
2. The injectable system of claim 1, wherein the degradable matrix is PLGA, with a selected L:G ratio, molecular
weight, and endcap.
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3. The injectable system of claim 2, wherein the PLGA
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has a L:G ratio of between 50:50 and 95:5, a molecular
weight between 5 and 300 kDa and an endcap of carboxylate
or ester-crosslinked hydrocarbon.
4. The injectable system of claim 1, wherein between 15
and 45 w/w % is the degradable matrix between 15 and 45
w/w % (+/-10%) is the ceramic and between 3-25 w/w %
(+/-10%) is the PBAE.
5. The injectable system of claim 1, wherein the system
comprises 19.5 w/w % degradable matrix, 45.5 w/w %
solvent, 30 w/w % ceramic and 5 w/w % drug-loaded PBAE.
6. The injectable system of claim 1, wherein the system
comprises 18 w/w % degradable matrix, 42 w/w % solvent,
30 w/w % ceramic and 10 w/w % drug-loaded PBAE.
7. The injectable system of claim 1, wherein the PBAE is
pre-loaded with a therapeutic agent, wherein the therapeutic
agent is selected from the group consisting of coldronate,
alendronate, etidronate, zoledronate, simvastatin, lovastatin,
rosuvastatin, SVAK-12, bone morphogenetic proteins, parathyroid hormone (1-34), metronidazole, doxycycline, vancomycin, gentamycin, ciprofloxacin, ketoprofen, celecoxib,
diclofenac, meloxicam or mixtures thereof.
8. A method of preparing the in situ injectable system of
claim 1, comprising mixing the degradable matrix,
microparticles and solvent.
9. The method of claim 8, wherein the microparticles are
preloaded with at least one pharmaceutical agent.
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10. The method of claim 8, further comprising crosslinking the degradable matrix.

11. The method of claim 9, wherein the microparticle are
mixed with the degradable matrix prior to cross-linking.
35

12. A method of treating osseous tissue, comprising
administering by injection the system of claim 1.
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